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ABSTRACT 
Skeletal Muscle Arteriole Dysfunction and Microvessel Density in Metabolic Syndrome and 
Depression: How Exercise Can Be Used as an Intervention                                                                                                          
Kayla W. Branyan 
The present study examined the effect of unpredictable chronic mild stress (UCMS) on 
peripheral microvessel function in healthy and metabolic syndrome (MetS) rodents, and whether 
exercise training could prevent the vascular dysfunction associated with UCMS. Our initial 
hypothesis was that: 1) LZRs exposed to UCMS would have peripheral microvascular dysfunction 
similar to that evident in the OZRs controls due to a reduction in NO bioavailability and an increase 
in ROS production; 2) the comorbidity between MetS exposed to UCMS will exacerbate the 
already existing peripheral microvascular dysfunction; 3) exercise could limit the peripheral 
microvascular dysfunction by decreasing oxidative stress and improving vasodilation associated 
with MetS exposed to chronic stress; 4) MVD will be reduced in rats exposed to UCMS but loss 
of MVD will be mitigated by exercise; and 5) the increase in MVD will be reflected by a change 
in angiogenesis and oxidative markers.   
Lean and obese (model of MetS) Zucker rats (LZR; OZR) were exposed to 8 weeks of 
UCMS, exercise (Ex), UCMS+Ex, or control conditions. At the end of the intervention, gracilis 
arterioles (GAs) were isolated and hung in a pressurized myobath to assess endothelium-dependent 
(EDD) and -independent (EID) dilation.  Levels of nitric oxide (NO) and reactive oxygen species 
(ROS) were measured through DAF-FM and DHE staining, respectively. Immunohistochemistry 
was used to determine the number of pericytes within the cortex and striatum of the brain.    
The comorbidity between UCMS and MetS does not exacerbate the effects of one another 
on GA EDD responses, but does lead to the development of other vasculopathy adaptations, which 
can be partially explained by alterations in NO and ROS production. Importantly, exercise training 
alleviates most of the negative effects of UCMS on GA function. Compared to LZR controls, EDD 
and EID was lower in LZR-UCMS. The OZR-Ex group had a higher EDD and EID, compared to 
OZR-Controls; whereas only a difference in EDD was noted between LZR-Control and LZR-Ex 
groups. Importantly, EDD and EID were higher in the LZR and OZR UCMS+Ex groups compared 
to UCMS alone. Lower NO bioavailability and higher ROS were noted in the LZR-UCMS group, 
but not OZR-UCMS, compared to controls. Ex and UCMS-Ex groups had higher NO 
bioavailability compared to control and UCMS groups, but ROS levels remained high. UCMS 
significantly decreased MVD in LZR-UCMS but was not changed in OZR-UCMS. In LZR- and 
OZR-Ex, MVD was increased and when coupled with UCMS, Ex improved MVD in both LZR- 
and OZR-UCMS+Ex. RT-PCR showed no differences in mRNA expression between groups in 
any of the angiogenic and oxidative stress markers examined. 
Corticosterone levels were elevated in the Ex and UCMS+Ex groups vs. the controls which 
may, in part, reflect the slight stress induced by use of the forced treadmill Ex protocol. It has been 
shown that glucocorticoids can increase ROS directly, including superoxide, hydrogen peroxide, 
and peroxynitrite (1). Given that DHE can interact with these oxidants, it could be speculated the 
higher ROS levels seen in LZR-Ex and UCMS+Ex are a byproduct of increased corticosterone. 
The fact that in Ex and UCMS+Ex EDD was improved despite elevated corticosterone levels, 
suggests EDD augmentation was likely mediated from non-corticosterone pathways. Previous 
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studies have also shown glucocorticoids can attenuate angiogenesis by inhibiting proliferation of 
cerebrovascular endothelial cells. In addition, pericyte apoptosis occurs with increased cortisol 
levels, where the glucocorticoid binds to receptors expressed on the pericytes to initiate cell death. 
L-NAME blunted maximum dilation back down to LZR- and OZR-Control+LNAME values, 
suggesting the Ex augmentation of EDD may be through a NO-dependent pathway. The expression 
and function of eNOS is upregulated after Ex training due to increased shear stress, thus could 
explain why EDD in LZR- and OZR-Ex was improved in the skeletal muscle arterioles. One 
possible factor that could have contributed to the increase in cerebral MVD could be the increase 
in NO production following Ex. Muscle contraction increases VEGF in the muscle interstitium, 
where VEGF acts on its receptors within the capillary endothelium to stimulate angiogenic 
processes, thus providing further support for exercise-induced angiogenesis.  
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CHAPTER 1 : Review of the Literature   
 
Peripheral Microvascular Structure and Function  
Resistance arteries are essential to sufficient blood perfusion of tissue. The aorta has been 
the focus in previous studies involving pathologies of the vascular system. Even though this blood 
vessel is important, there is a need to explore the impact of disease on resistance arteries. 
Resistance arteries and arterioles are the primary vessels in regulating blood pressure and flow 
at/within an organ. They are located after small arteries but right before the capillaries (Figure 1-
1). These resistance vessels further dampen the pulsatility of blood coming from the aorta. Once 
blood reaches the small arteries, there is a 50-70% decrease in pressure (2). This dissertation will 
focus specifically on resistance arterioles within the skeletal muscle, and partially on the cerebral 
microvasculature.    
 
Figure 1-1 Cardiovascular Physiology Concepts. Klabunde 
2016. 
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The structure of an arteriole is optimized for its function. The diameter of the vessel is 
small, and the tunica media consists of fewer smooth muscle cell layers than what is seen in 
muscular and elastic arteries. These vascular smooth muscle cells keep the arteriole in a partially 
constricted state, called basal vascular or vasomotor tone (3). Central control processes and local 
regulatory mechanisms alter the contractile activity of the vascular smooth muscle (2,4). On the 
smooth muscle, there are membrane receptors, ion channels, and mechanical sensors that respond 
to changes in blood flow, along with second messenger systems that are activated by gaseous 
signaling molecules. These factors illustrate the complexity of the regulation of vascular tone to 
control blood flow (4). Vasomotor control properties vary along the arteriolar branch but also 
among the different types of skeletal muscle fibers (5).     
 
Skeletal muscle arteriole function  
Resistance arteries and arterioles are highly innervated by the sympathetic nervous system 
(2). The sympathetic nervous system acts on peripheral arteries and arterioles during times of 
increased cardiac demand. Sympathetic input constricts these blood vessels to increase resistance 
and decrease distal blood flow. The downstream effect of resistance artery constriction is an 
increase in cardiac output, systemic vascular resistance, and arterial blood pressure. The main 
nerves innervating resistance arteries are sympathetic adrenergic nerves that release 
norepinephrine (NE) as a neurotransmitter. NE binds to α1-adrenoceptors to cause smooth muscle 
contraction, thus vasoconstriction. A common pharmaceutical drug that is used in studies because 
of its actions as a α1-adrenoceptor agonist is phenylephrine (PE). Vasodilation can be achieved by 
stimulation with epinephrine (EPI) which binds to β2-adrenoceptors, but this is highly 
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concentration dependent. Acetylcholine (Ach) is another neurotransmitter involved in 
vasodilation, where it binds to muscarinic receptors (specifically M3) on the endothelium to trigger 
the production of nitric oxide (NO) to prevent smooth muscle contraction (2).   
There are several vascular signal transduction mechanisms including G-protein coupled 
and cGMP-coupled signaling. G-protein coupled signaling involves three different G-proteins: Gs, 
Gi, and Gq.  Gs-proteins stimulate adenylyl cyclase to catalyze the formation of cAMP. This causes 
relaxation of the smooth muscle because the increased cAMP inhibits myosin light chain kinase 
activity. The Gs-proteins are coupled to β2-adrenoceptors (EPI and isoproterenol), α2-purinergic 
receptors (adenosine), and IP receptors (prostacyclin). α1-adrenoceptors are coupled to Gi-proteins 
and when NE binds, there is a reduction in cAMP leading to smooth muscle contraction (2).   
Gq-proteins are coupled to three different receptors: α1-adrenoceptors (NE), ETA receptors 
(endothelin-1; ET-1), AT1 receptors (angiotensin II), and V1 receptors (vasopressin). Instead of 
stimulating adenylyl cyclase, Gq-proteins activate the phospholipase C pathway and the Rho-
kinase pathway to cause smooth muscle contraction (2).  
Eighty percent of ET-1 is released towards the vascular smooth muscle cells where it binds 
to ETA receptors to cause vasoconstriction. Another isoform of the ET-1 receptor, ETB, is 
expressed on both smooth muscle and endothelial cells (6). When ET-1 binds to this receptor on 
endothelial cells, it promotes the production of NO and prostacyclin which then diffuse into the 
smooth muscle to cause relaxation (4).  
 Under basal conditions, cyclooxygenase-1 (COX-1) is active in endothelial cells to convert 
arachidonic acid to prostaglandin H2 (PGH2). PGH2 is then converted to either prostacyclin 
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(PGI2) or thromboxane A2 (TxA2) by their respective synthases. PGI2 causes vasodilation and 
TxA2 induces vasoconstriction (7).  
NO is produced from the combination of L-arginine and molecular oxygen by the 
enzymatic activity of endothelial nitric oxide synthase (eNOS), inducible NOS (iNOS), and 
neuronal NOS (nNOS). cGMP-signaling within the vasculature involves the production of NO 
from eNOS, which diffuses into the smooth muscle to activate soluble guanylyl cyclase and 
increases cGMP formation to cause vasodilation (2) (Figure 1-2). Activation of eNOS is 
complicated and can be done through several different pathways. Adenosine, Ach, and NE can 
activate eNOS after binding to their respective receptors. During inflammatory conditions, 
bradykinin, calcitonin gene-related peptide, and substance P can also activate eNOS. Mechanical 
forces can activate eNOS, such as flow- or shear-dependent vasodilation. eNOS is also activated 
by the binding of calcium-calmodulin and post-translational control mechanisms including: 
phosphorylation of activation sites, fatty acid modification, and protein-protein interactions (8,9). 
Treatment with L-NG-nitroarginine methyl ester (LNAME), a NOS inhibitor, abolishes 
Figure 1-2. Normal endothelial function. Adapted from 
Bruyndonckx et al. 2013. 
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endothelium-dependent dilation and even causes significant vasoconstriction in a variety of 
vascular beds, providing evidence that NO is crucial to proper endothelial function (10–12).       
 
Myogenic Response        
 Skeletal muscle arteriole smooth muscle responds to changes in transmural pressure, the 
difference between intravascular and extravascular pressure.  When transmural pressure increases, 
smooth muscle contracts and luminal diameter is reduced to increase the resistance to blood flow.  
A decrease in transmural pressure causes an increase in luminal diameter.  This reaction is called 
the myogenic response.  The myogenic response keeps the arteriole in an intrinsic, steady-state of 
contraction, allowing it to change vessel diameter in either direction in response to stimuli 
(3,13,14).  Shear stress-induced vasodilation operates by mechanisms inherent to the blood vessel 
wall such that alterations in smooth muscle tone independent of changes in intravascular or 
transmural pressure can be produced in vessels isolated from the surrounding tissue and perfused 
in an ex vivo system (15–18).            
 
Autoregulation of blood flow 
 The maintenance of relatively constant perfusion of an organ is essential to proper function.  
Most tissues, like skeletal muscle, are capable of autoregulating their blood flow in relation to 
changes in mean arterial pressure (MAP). If MAP is reduced, skeletal muscle blood flow falls, at 
least initially. Decreased blood flow increases the number of vasodilator metabolites within the 
tissue to cause vasodilation; blood flow is restored to near normal levels. The opposite is true when 
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MAP increases. The increase in arterial pressure enhances vasodilator metabolite washout, leading 
to vasoconstriction and a restoration of blood flow toward normal levels (19,20).   
 
Cerebral Microvascular Function 
The brain is the most perfused organ in the body, and obviously for important reason. In 
order for essential nutrient exchange to occur, the microcirculation of the brain must be highly 
regulated. Capillary density varies significantly within the brain, depending on region and energy 
needs. This density is influenced by pathological, physiological, and environmental factors (21).  
For example, hypertension affects brain capillary density the same way it affects peripheral 
microcirculation, causing rarefaction and impaired microvessel formation that leads to increased 
vascular resistance. The structure of brain capillaries is unique compared to their peripheral 
counterparts (Figure 1-3). Pericytes and astrocytes are crucial to cerebral capillary function by 
regulating cerebral blood flow, upregulating tight junction proteins, contributing to ion and water 
homeostasis, and interfacing directly with neurons (22–25).   
 Pericytes are adjacent to capillaries and share a common basement membrane with 
endothelial cells. In fact, the ratio of pericyte-to-endothelia is high compared to the vasculature of 
other organs (1:3 in brain vs 1:100 in skeletal muscle) (26). These cells are thought to have several 
roles in the brain such as contributing to the stability of the vessel, release of growth factors and 
matrix important for microvascular permeability, remodeling, and angiogenesis (27). Another 
essential structural component to the brain vasculature is collateral circulation. The collateral 
vascular network allows for maintenance of cerebral blood flow, if and when primary inflow fails 
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due to occlusion or constriction. The circle of Willis provides low-resistance connections to the 
anterior and posterior circulations, allowing for reversal of blood flow if needed (28).       
  
Autoregulation of the brain microvasculature is the most important mechanism to ensure 
constant and sufficient perfusion. The capillaries of the brain are perfused with blood at all times 
and each have their own neuron. When the resistance arteries and arterioles dilate, the 
microvascular pressure gradient increases, thus increasing capillary flow.  Red blood cell velocity 
is high in the cerebral capillary microcirculation to provide efficient oxygen transport to the highly 
metabolic neuronal tissue (29). The microvessel innervation is intrinsic, meaning each vessel is 
innervated from within the brain tissue. The nerve terminals do not, however, contact the arteriole 
itself but rather targets astrocytes surrounding the vessel (30). Middle cerebral artery (MCA) 
smooth muscle cells are contracted by the binding of serotonin (5-HT) to α1-adrenoreceptors to 
cause activation of the phospholipase C-protein kinase C pathway (31). Interestingly, sympathetic 
stimulation has little effect on resting cerebral blood flow under normotensive conditions. In 
contrast, parasympathetic stimulation has potent effects on cerebral arteries, and increases cerebral 
blood flow (32). Neuronal NO is important for modulating cerebral blood flow autoregulation. 
Other vasoactive substances such as H+, K+, O2, and adenosine are released to cause vasodilation 
Figure 1-3. Schematic of the neurovascular unit. Neuron 2008;57:178–201 
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when cerebral blood flow is reduced.  When blood flow pressure is at the high end of the 
autoregulatory curve, regulation is probably due to the myogenic response of the cerebral smooth 
muscle to constrict in response to elevated pressure.  Evidence for the crucial importance of 
autoregulation in normal brain function is provided by the fact that significant brain injury occurs 
when this autoregulatory mechanism is lost (33–35). Another protective mechanism for the 
cerebral circulation is segmental vascular resistance, meaning both large arteries and small 
arterioles contribute significantly to vascular resistance. This mechanism helps to provide constant 
blood flow in the brain to meet high metabolic demand, without pathologically increasing 
hydrostatic pressure (36,37).     
 
Metabolic Syndrome (MetS)  
Thirty-five percent of all American adults and 50% of those aged 60 years and older present 
with MetS (38). There is a 3-fold increased risk for CVD with MetS and the syndrome alone 
predicted 25% of all new-onset CVD (39). The conditions that underlie the metabolic syndrome, 
including most types of cardiovascular disease, have a cumulative cost of over $300 billion in the 
US annually, which comprises the largest financial burden on the US healthcare system. For 
contrast, the annual cost of all types of cancer is just under $90 billion (38,40). MetS is defined by 
the co-occurrence of several cardiovascular risk factors including insulin resistance, obesity, 
atherogenic dyslipidemia, and hypertension. Previous research has shown that these risk factors 
are not independent of one another and they share underlying causes, mechanisms, and features 
(41,42). The current definition of MetS is centered on insulin resistance and obesity. Insulin 
resistance is measured as impaired fasting glucose or glucose tolerance. An increased homeostatic 
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model assessment of insulin resistance (HOMA-IR) is also indicative of insulin resistance. The 
diagnosis of MetS is contingent on the patient presenting with three or more of the criteria.   
Insulin stimulates the synthesis of glycogen from glucose and inhibits glycogenolysis in 
the liver and skeletal muscle. Lipolysis is inhibited, and glucose uptake is stimulated by insulin in 
adipose tissue. Insulin signaling activates two pathways: the phosphoinositide 3-kinase (PI3K) and 
mitogen-activated protein kinase (MAPK) pathways. PI3K activates Akt kinase which 
phosphorylates and activates eNOS in vascular endothelial cells. Akt kinase also stimulates 
translocation of the insulin-responsive glucose transporter GLUT4 to the cell surface, leading to 
increased glucose uptake. Activation of the MAPK pathway mediates ET-1 production, leading to 
vasoconstriction; expression of the vascular cell adhesion molecules VCAM-1 and E-selectin, 
leading to more leukocytes-endothelial interactions; and growth and mitogenesis effects on 
vascular smooth muscle cells.   
Low levels of ROS contribute to normal physiological cell signaling but when there is 
excessive production or impaired buffering of ROS, there can be deleterious effects. Many 
pathologies augment the production of ROS from nicotinamide adenine dinucleotide phosphate 
oxidase (NOX), xanthine oxidase (XO), cyclooxygenases (COX), and even eNOS. ROS, such as 
superoxide, degrades NO by binding to it to form peroxynitrite. Peroxynitrite is a highly unstable 
free radical that causes endothelial damage, and NO bioavailability is lowered. NOX is the 
predominant source of superoxide and is found in both endothelial and smooth muscle cells.   
Superoxide dismutase (SOD) usually breaks down superoxide anions into hydrogen peroxide but 
under pathological conditions, SOD function decreases and leads to an impaired buffering of ROS.  
Experimental inhibition of SOD results in impaired agonist-evoked endothelium-dependent, NO-
mediated dilation (43–46).   
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Other endogenous antioxidant systems exist in the vasculature including glutathione and 
hydrogen peroxide-reducing enzymes, glutathione peroxidase and catalase. Supplemental 
treatment with antioxidants acutely improve endothelium-dependent relaxation in vitro and in vivo 
(47–50). 4-hydroxy-TEMPO (TEMPOL) is a common pharmaceutical agent used to scavenge free 
radicals. Previous studies have shown that both acute and chronic treatment with TEMPOL can 
increase NO bioavailability and improve endothelium-dependent dilation response (51,52). ROS 
can effect eNOS directly through S-glutathionylation to inactivate the enzyme (53).   
MetS encompasses a variety of different factors that contribute to endothelial dysfunction 
(Figure 1-4). Other contributors to endothelial dysfunction associated with MetS include: 
increased ROS production by oxidase complexes leading to damages of the insulin receptors; 
increased insulin receptor substrate (IRS)-1 phosphorylation at Ser307; induction of ET-1 
expression in the endothelium; exaggerated activation of endothelial mineralocorticoid receptors 
by aldosterone; and increased production of tumor necrosis factor-α (TNF-α) (54). MetS alters 
arachidonic acid metabolism and shifts the pathway from mainly vasodilatory to vasoconstrictor 
Figure 1-4. Normal versus impaired endothelial function. Bruyndonckx et al. 2013. 
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metabolites (55,56). Results from previous studies suggest that insulin resistance and increase 
oxidative stress contribute to enhanced TP activation which is independent of increased TxA2 or 
TP activity (57).          
Blood flow must meet the metabolic demands of the tissue and where this is especially 
important is the skeletal muscle and brain. The microvascular network is optimized for meeting 
these demands but under pathological conditions, structural alterations to the network can elevate 
vascular resistance and impair functional hyperemic responses (58). This includes the loss of 
microvessels within the tissue, or microvascular rarefaction. Microvascular rarefaction can also 
decrease the ability of skeletal muscle to resist fatigue through impairments in the processes of 
mass transport and exchange (59,60). The extent of rarefaction is correlated with a loss in NO 
bioavailability, suggested by previous studies that used physiological and pharmacological 
interventions to maintain NO levels and the severity of microvascular rarefaction was blunted (61–
65). Fluctuations in markers of inflammation and oxidative stress, such as TNF-α, nitrotyrosine, 
and thromboxane, have been shown to be predictive of microvessel density changes (66).   
Previous studies have provided evidence for a link between the balance of systemic 
vascular oxidant stress and endothelial function and progression/severity of microvascular 
rarefaction (66–68). This suggests that NO bioavailability is also linked to microvascular 
rarefaction because rarefaction followed the reduction in NO levels, and interventions aimed at 
improving NO bioavailability were the most effective in blunting the severity of rarefaction 
(69,70).   
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Insulin Resistance 
Insulin resistance affects the PI3K-Akt pathway but not the MAPK pathway. This means 
NO production is reduced and ET-1 and expression of adhesion molecules are unaffected (71). 
During insulin resistance conditions, adipose, skeletal muscle, and liver cells do not respond 
appropriately to insulin, and circulating glucose levels remain high. Insulin resistance causes a 
reduction in eNOS phosphorylation; thus, the endothelium-dependent, NO-mediated relaxation 
response is blunted. As a common pathway in CVD and in the development of atherosclerosis, 
endothelial dysfunction is affected by each of the constituent risk factors of MetS. The major 
feature of endothelial dysfunction is a reduction in NO bioavailability. eNOS activation by 
phosphorylation at Ser-1177 is diminished by insulin resistance. Activation of eNOS is essential 
to the hemodynamic actions of insulin, thus during insulin resistance blood flow to skeletal muscle 
is reduced. ET-1 expression and vascular smooth muscle mitogenic effects are not affected by 
insulin resistance, therefore exacerbating endothelial dysfunction. TNF-α blocks IRS-1 activation 
and directly activates NOX to increase superoxide generation. This cytokine also stimulates 
lipolysis, resulting in FFA release (72). 
 
Visceral adiposity 
 Obesity causes a reduction in NO-mediated, endothelium-dependent relaxation because of 
increased ROS production and decreased phosphorylation of eNOS (73,74). The release of 
endothelium-derived vasoconstrictor prostanoids and ET-1 is also upregulated. Previous studies 
have found that caloric restriction, weight loss, and exercise training improve endothelium-
dependent responses, which could partially be explained by deacetylation and activation of eNOS 
by SIRT1 (75). Free fatty acids diminish PI3K-Akt signaling, increase ROS, and increase ET-1 
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production (71,76–78). As another major risk factor of MetS, visceral obesity causes a decrease in 
insulin-mediated glucose uptake through adipokine signaling including TNF-α and IL-6.  
Adiponectin is a protective adipokine that couples insulin sensitivity with energy metabolism but 
adiponectin levels are decreased in obesity and MetS. Adiponectin attenuates ET-1-induced 
vasoconstriction in normal, healthy conditions but with obesity, adiponectin levels are decreased 
and the imbalance of ET-1 vs. adiponectin could contribute to insulin resistance. Further, ET-1 
stimulates reactive oxygen species (ROS) production by NAPDH oxidase, thus promoting 
oxidative stress-induced vascular dysfunction (4,79).       
 
Atherogenic dyslipidemia 
 Dyslipidemia is characterized by high plasma triglyceride levels, low HDL cholesterol 
levels, and an increase in small dense LDL. Insulin resistance and dyslipidemia are causative 
factors of one another. Insulin normally suppresses lipolysis in adipocytes, thus when insulin 
signaling is impaired there is an increase in lipolysis and increase of free fatty acid levels. apoB, 
the major lipoprotein of very-low-density lipoprotein (VLDL) particles, is stabilized by free fatty 
acids resulting in more VLDL production. Insulin also regulates the activity of lipoprotein lipase, 
the major mediator of VLDL clearance. If HDL is triglyceride-rich, hepatic lipase can rapidly clear 
it from the circulation to leave fewer HDL particles to participate in reverse cholesterol transport 
from the vasculature. This perpetuates the dyslipidemia associated with MetS (39,71,80).   
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Hypertension 
The generally accepted view of hypertension is it causes premature aging of the vasculature 
because it is exposed to chronically increased arterial blood pressure. It has been shown that NO 
bioavailability is reduced, thus causing a reduction in endothelium-dependent dilation response.  
A variety of different mechanisms have been proposed as to why NO is decreased. Perticone et al, 
(81) attributed lower NO bioavailability in hypertension to higher circulating levels of asymmetric 
dimethylarginine (ADMA). High blood pressure can cause epigenomic DNA methylation and 
RNA processing changes which alter gene expressions, increase oxidative stress, and precipitate 
senescence of endothelial cells (82). Increased intraluminal pressure can also increase local 
angiotensin signaling and further augment oxidative stress (83). All of these factors lead to 
endothelial dysfunction. A chronic increase in perfusion pressure, in the case of hypertension, also 
causes microvascular rarefaction (84).     
 
Animal model of MetS 
 Lois Zucker discovered the fa mutation in a cross between Merck M-strain and Sherman 
rats, and rats that are homozygous for this allele present with a missense mutation in the leptin 
receptor (85).  These rats are named obese Zucker rats (OZR).  Leptin is released by adipose tissue 
in proportion to the amount of lipids stored and acts in the brain to determine a decrease in food 
intake and an increase in energy expenditure.  By 3-5 weeks, the OZRs become noticeably obese 
as a result of hyperphagia, and develop defective non-shivering thermogenesis and preferential 
deposition of energy into adipose tissue.  These animals also have elevated circulating leptin levels 
as compared to their lean counterparts.  At 14 weeks, the body composition of the obese Zucker is 
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approximately 40% lipid weight (85,86). The OZRs also present with dyslipidemia, insulin 
resistance, and mild glucose intolerance. 
Mesenteric arterial function is reduced in OZRs.  Wu et al. (87), found the endothelium-
dependent dilation response to Ach was significantly reduced and incubation with LNAME 
inhibited dilation even further.  This study and others suggest endothelial dysfunction in OZRs, 
perhaps by a decrease in NO bioavailability (88–92). A study by Frisbee and Stepp (89) confirmed 
this finding, but in the cremaster muscle arteriole. Further, the study attributed the decrease in 
dilation response to increased levels of superoxide which in turn ameliorated NO levels.    
MetS is associated with microvascular rarefaction along with endothelial dysfunction.  
Chantler et al. (70), showed a decrease in cerebral cortical MVD in OZRs by 12-13 weeks.  
Cerebral MVD was reduced by 20% in 16-17-week-old OZRs as compared to LZR controls.  This 
study used two pharmaceuticals prescribed for glycemic control and found they were effective in 
reducing plasma levels of nitrotyrosine (marker of oxidative stress) and blunting microvascular 
rarefaction (70).  It is important to note that MetS-associated loss of MVD is not solely present in 
the brain, but also in the skeletal muscle.    
Lash et al. (93), compared the capillary density (CD) and capillary basement membrane 
(CBM) thickness in the plantar muscle of sedentary and trained OZRs to those of lean Zucker rats 
(LZR).  At 11 weeks of age, OZRs had lower CD and thicker CBM than LZRs.  CD and CBM 
decreased proportionally greater in OZRs from 11 weeks to 18 weeks.  Exercise training for 6 or 
12 weeks significantly increased CD in 18-week OZRs.  A study by Xiang et al. (94), showed 
exercise training could also improve skeletal muscle microvascular function, specifically by 
augmenting endothelium-dependent dilation. 
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The collective factors of MetS cause direct endothelial injury, resulting in vascular 
remodeling.  Lumen remodeling occurs in three ways: hypotrophic (thinned), eutrophic (invariant), 
or hypertrophic (thickened).  Thickening of the vessel wall usually occurs by vascular smooth 
muscle cell proliferation and migration, impaired integrity of elastin fibers, and deposition of 
extracellular matrix (95).      
MetS causes an increase in circumferential wall stress and flow-mediate shear stress, 
leading to vascular remodeling. Specifically, carotid wall thickness is increased as is lumen 
diameter (96–98). In OZRs, the microvasculature has been shown to undergo atrophic remodeling, 
a reduced lumen size and thinner vascular walls (99). The coronary resistance microvessels in a 
swine model of MetS demonstrated inward hypertrophic remodeling (100). Vascular remodeling 
is variable, possibly site- and animal-dependent (101).  MetS causes arterial stiffening, which may 
be due to decreased NO bioavailability, smooth muscle cell proliferation, and increased synthesis 
of structural proteins including collagen. The chronic inflammation associated with MetS can also 
induce release of matrix metalloproteinases (MMPs). Leukocytes can facilitate outward 
remodeling, while macrophages can expedite inward remodeling (102). Further, local hormones 
such as angiotensin II induces hypertrophy of vascular smooth muscle cells and increases collagen 
production by fibroblasts (103).           
 A disease that is often underdiagnosed and undertreated is peripheral artery disease (PAD).  
PAD is associated with an elevated risk of poor cardiovascular outcomes such as myocardial 
infarction, stroke and even death. More than 200 million people have PAD worldwide. Pain related 
to PAD causes patient quality of life to diminish as mobility and independence are progressively 
reduced, often exceeding the loss of function seen in patients with other forms of cardiovascular 
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disease (CVD) (104). The individuals most affected by PAD are those 50 years and older, with a 
sharp rise in prevalence around the age of 70 (105).        
 
The risk factors associated with PAD correlate with those of CVD. The first is diabetes 
mellitus which is estimated to attribute to PAD in 14% of patients (106). The duration of diabetes 
mellitus, level of glycemic control, and use of insulin are strongly correlated with the increased 
risk of PAD (107,108). Diabetic patients with PAD have worse outcomes such as an increased 
amputation risk and 3-times higher odds of mortality (109) (Figure 1-5).   
 Several other risk factors for PAD are hypertension, dyslipidemia, obesity, and increased 
C-reactive protein. These are not just risk factors for PAD, but also fall under the cluster of factors 
that constitute MetS. Hypertension and systolic blood pressure were found to be significantly and 
independently associated with PAD. The higher prevalence of PAD in elderly patients renders 
hypertension a major contributor to the total burden of PAD in the population (110). The ratio 
between total cholesterol and HDL-C is another measure for increased risk of PAD. The typical 
dyslipidemia seen in insulin-resistant individuals (low HDL-C and high triglycerides) is 
Figure 1-5. 10-year survival rate for patients with and without PAD. San 
Diego Artery Study, 1992. 
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significantly associated with PAD (111). Although obesity has not been found to be independently 
associated with PAD, the factors linked to obesity, like the ones previously stated, contribute to 
PAD. A higher waist/hip ratio has been found to be significantly correlated with a higher risk of 
PAD even though BMI or body fat percentage were not (108). An increase in inflammatory 
markers, such as C-reactive protein, have also been shown to contribute to PAD risk (112). 
 
Chronic Stress and Depression  
 Diagnosing depression is actually problematic because distinguishing mood changes 
between clinical and normally occurring is difficult. Depressive symptoms in and of themselves 
are complex, characterized by the absence of a positive effect (anhedonia), low mood, and a range 
of associated emotional, cognitive, physical and behavioral symptoms. Major depression is based 
on its severity, persistence, the presence of other symptoms, and the degree of functional and social 
impairment but there is no distinct ‘cut-off’ between ‘major’ and ‘normal’ degrees of depression 
(113,114).         
 In major depressive disorder, mood remains low throughout the day and does not change 
with circumstance. Within other forms of depression, mood can be reactive to positive experiences 
and events, but depressive feelings return/reemerge quickly after the event is over (115). Physical 
and behavioral symptoms include tearfulness, irritability, social withdrawal, and exacerbation of 
pre-existing pains, pains secondary to increased muscle tension, a lack of libido, and fatigue and 
diminished activity. In some patients sleep and appetite are lowered but in others, sleep and 
appetite are increased. Other behavioral changes associated with depression include: loss of 
interest and enjoyment in everyday life, feelings of guilt, worthlessness and that one deserves 
punishment, lowered self-esteem, loss of confidence, and suicidal ideation. Poor concentration and 
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reduced attention, pessimistic and recurrently negative thoughts about oneself, one’s past and the 
future, and mental slowing are all cognitive changes that occur with depression (116,117).   
 It used to be thought that depression was time-limited and although it is episodic, 
incomplete recovery and relapse are very common. Fifty percent of people will have at least one 
more episode after their first, and after the second and third episodes, the risk of further relapse 
rises to 70 and 90%, respectively (118). As the most common mental disorder, depression is a 
major cause of disability across the world. There is a strong correlation between illness severity 
and the extent of disability (119). Depressive illness causes a greater decrement in health state than 
the major chronic physical illnesses such as angina, arthritis, asthma, and diabetes (120). The 
emotional and cognitive effects of depression substantially reduce a person’s ability to work 
effectively, which increases dependence on welfare and benefits and reduces personal income.  
When coupled with pre-existing physical diseases, health is worsened as compared with physical 
disease alone and increases risk of death (117,120).   
 The etiology of depression spans many different physiological processes and factors.  
Diabetes, cardiac disease, diseases of the thyroid, Cushing’s syndrome, and Addison’s disease 
have all been shown to increase the risk of depression (117). Interestingly, some psychological 
disorders have been found to be significantly correlated with PAD such as anxiety and depressive 
symptoms (121). The prevalence of depression in PAD is similar to that in CVD, which is from 2-
10%. Depression has been linked with certain risk factors for PAD including coronary artery 
disease, hypertension, and diabetes mellitus. Hippisley-Cox et al. (122), found that 20% of 
depressed patients also had coronary artery disease and Frasure-Smith et al. (123), showed a 
significant increased mortality in patients with comorbid depression and coronary artery disease.  
Patients with hypertension are three times as likely to have concurrent major depression (124). In 
21 
 
individuals with diabetes mellitus, the mean prevalence of depression is 32% (125). The fact that 
PAD risk factors are significantly related to depression suggests there is a bi-directional causality 
between the two. Brostow et al. (126) examined the link between the physical dysfunction caused 
by PAD and the negative affect of depression on walking ability. The study made the connection 
that depressed PAD patients may experience a multifactorial burden of disease because PAD 
directly impacts patients’ ability to walk and depression is also an independent predictor of 
disability and loss of mobility (126). Another study by Smolderen et al. (127) found that depressed 
PAD patients performed worse on the treadmill exercise test.  
 
Chronic Stress 
  The state of threatened homeostasis, or stress, is caused by intrinsic and/or extrinsic adverse 
forces (stressors). The body then tries to counteract these stressors by activating physiologic and 
behavioral responses to reestablish equilibrium. Chronic stressors have the most detrimental 
effects on physiological functions including growth, reproduction, metabolism, 
immunocompetence, and behavior and personality development (128). In addition to these effects, 
chronic stress acts as a pre-disposing and participating factor in the onset of depression in humans 
(129–131).    
Part of the stress response system includes the hypothalamic-pituitary-adrenal (HPA) axis.  
Corticotropin-releasing hormone (CRH) acts to regulate the anterior pituitary adrenocorticotropic 
hormone (ACTH). Under normal, non-stressful conditions, CRH and vasopressin are secreted in a 
circadian fashion but also pulsatile with a pulse of production every 1-2 hours. The production of 
CRH and vasopressin increase in the early morning hours (132,133). Acute stress augments CRH 
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and vasopressin production and induces the production of Ang II and various cytokines and lipid 
mediators of inflammation, leading to further activation of the HPA axis (134).   
ACTH targets the adrenal cortex to regulate glucocorticoid and adrenal androgen secretion.  
Cortisol secretion is increased during times of stress, and can be regulated by other hormones and 
cytokines coming from the adrenal medulla or systemic circulation (135). Glucocorticoids increase 
hepatic gluconeogenesis and glucose plasma levels, induce lipolysis, and cause protein degradation 
in multiple tissues. Therefore, chronic HPA axis activation can have detrimental effects including 
increased visceral adiposity, suppressed osteoblastic activity, decreased lean body mass, and 
insulin resistance (136–138). Previous studies have shown that chronic stressors increased the 
incidence of visceral obesity and MetS (138,139). In addition to accumulation of visceral adipose 
tissue, chronic stress strongly correlates with behavioral changes that decrease physical activity 
and poor dietary habits, therefore leading to further weight gain and potentially to dysregulation 
of glucose and lipid metabolism (140,141).    
Under chronic systemic inflammation situations, such as in MetS, prolonged increased 
circulating levels of pro-inflammatory cytokines can lead to hyperactivation and derangement of 
the HPA axis (142). Adipocytes specifically release pro-inflammatory cytokines such as TNF-α 
and IL-6 that can chronically stimulate the HPA axis to induce a vicious cycle whereby 
hypercortisolemia contributes to adipocyte accumulation and vice versa (80,143). After chronic 
exposure to high aldosterone levels NO-dependent relaxations are impaired, perhaps due to a 
reduction in BH4 production and an increase in oxidative stress, thus augmenting the release of 
vasoconstrictor prostaglandins (144). Endothelium-dependent reactivity is reduced under 
chronically high cortisol levels, probably due to a decrease in eNOS expression (145).     
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 Little is known about how chronic stress and depression directly impact vascular structure 
and cause remodeling. Aldosterone has been shown to decrease vascular integrity by disrupting 
endothelial remodeling, specifically by modifying the actin cytoskeleton assembly. Cortisol was 
found to partially mimic this effect by aldosterone where it significantly increased paracellular 
permeability and influenced distribution of junction-associated proteins (146).   
 
Unpredictable Chronic Mild Stress Model 
 Unpredictable Chronic Mild Stress (UCMS) is a well-known, validated animal model using 
chronic stress to induce depressive symptoms. Most studies that use this model have documented 
physiological changes in the brains of rodents, mainly reflecting an elevated physiological stress 
response (147). The effects of UCMS have been attributed to its impact on the HPA axis, shown 
by the prevention of a depressive phenotype when glucocorticoid receptors are inhibited (148–
151) and development of depressive symptoms when exogenous corticosterone is given 
(149,150,152).       
 Changes in NO levels have been discovered in chronic stress-induced depression patients 
but it is unclear in humans whether bioavailability is increased or decreased (153,154). In animals, 
however, Gao et al. (155) have shown an increase in plasma NO levels and decrease in total NOS 
activity. Isingrini et al. (156), illustrated an overall decrease in endothelium-dependent dilation 
response of the aorta in UCMS. The maximum response was significantly lower in UCMS as 
compared to the control group (156). Oxidative stress associated with chronic stress and depression 
directly decrease NO bioavailability. Zhou et al. (157), found that nNOS mRNA and protein 
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content were elevated in the hippocampus. nNOS enzymatic activity was also enhanced, consistent 
with the increase in expression (157).   
 
Exercise 
Acute Effects  
Initiation of exercise causes drastic changes in hemodynamics through different 
mechanisms. The sympathetic nervous system directs increased sympathetic outflow to the heart 
to increase cardiac output and evokes baroreflex-mediated vasoconstriction in peripheral organs 
to redirect blood flow to contracting skeletal muscles and maintain blood pressure (158,159). This 
process is called functional hyperemia. Exercise creates a ‘muscle-pump’ to increase the blood 
flow to the active muscles.           
Dilation of the arterioles is important to provide sufficient blood flow to meet the increased 
demand for oxygen. Vasoactive metabolites such as potassium ions, adenosine, and NO from the 
muscle, all generate vasodilation (160,161). Through the production of adenosine and NO, 
sympathetic vasoconstrictor tone in exercising muscles is lessened, a process known as functional 
sympatholysis.     
 Exercise inherently increases shear stress within the lumen of blood vessels, which 
contributes to the regulation of vascular tone (162). The increase in shear stress acts to trigger 
vasodilation, mainly through NO release from endothelial cells, but also hydrogen peroxide, 
epoxyeicosatrienoic acids, and PGI2. ATP released from endothelial cells stimulates purinergic 
receptors to induce NO production from endothelial cells. It has also been shown that in response 
to laminar shear stress, eNOS mRNA expression is upregulated (163). All of these factors caused 
by shear stress aid in vasodilation to provide proper perfusion of active skeletal muscle.   
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Sudden increases in shear stress induce bursts of PGI2, a vasodilator, to be released. In the 
skeletal muscle arterioles, PGI2 plays a larger role in flow-mediated vasodilation than it does in 
conduit arteries. After short-term daily exercise the gracilis muscle arteriole response to wall shear 
stress was upregulated and resulted in an augmented dilator response, perhaps due to increased 
NO and prostacyclin (164). Continuous release of NO and prostacyclin, enhanced by shear stress, 
can counteract neurogenic and myogenic vasoconstriction in vivo (165).      
Previous studies have shown that short-term exercise increased endothelial NO synthesis 
in skeletal muscle arterioles and increased the vasodilator response to Ach. Endothelium-
dependent dilation was improved in conduit arteries as well (166). These results suggest that short-
term exercise training enhances NO production and activity to buffer increased shear stress.  
Active muscles release myokines such as IL-6 and IL-8. IL-6 is known to influence AMP-
activated protein kinase (AMPK). It is thought that through this pathway, vasodilation is activated 
by AMPK phosphorylating eNOS to produce NO. Skeletal muscle also highly expresses neuronal 
NOS (nNOS), which enhances the production of IL-6 (167).   
 
Chronic Effects  
Adaptive changes in skeletal muscle circulation are found after chronic exercise training 
to improve blood flow capacity and oxygen diffusing capacity. Mainly this occurs through 
angiogenic adaptations and remodeling of the vasculature (160,168–170), but it also exerts 
beneficial effects on vascular reactivity. 
The periodic increases in blood flow improve endothelium-dependent vasodilation by 
modulating the expression of NO synthase. The magnitude and nature of shear stress has influence 
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on endothelial cell NO synthesis, where laminar shear stress dose dependently upregulates NO 
synthesis but turbulent shear stress has no effect on the NO synthase pathway (171). One 
mechanism by which flow augments NO synthase is through an increase in the involvement of 
shear stress responsive elements within the promoter region of the gene. The sequence for these 
shear stress responsive elements is also common in other endothelial genes that respond to shear 
stress including tissue plasminogen activator, intracellular adhesion molecule, TGF-β, PDGF-β, 
and ET-1 (172,173).  
Flow-mediated vascular remodeling is endothelium-dependent. With chronic low flow, 
vessel diameter decreases but the opposite is true for a chronic increase in flow. It is proposed that 
the endothelium induces changes in vessel structure by producing vascular growth-mediators such 
as NO, TGF-β, PDGF-β, ET-1, PGI2, and tissue plasminogen activator (15,164,174–178).   
  Exercise increases capillary density and arteriolar number. The stimulation of 
angiogenesis may be derived from perivascular or stromal cells responding to mediators and 
mechanical forces associated with exercise to release angiogenic factors such as vascular 
endothelial growth factor (VEGF) and NO, thus inducing vascular remodeling (179,180). IL-8 
seems to be involved with the angiogenic response to exercise. This particular myokine can affect 
pericyte function, which is essential for endothelial lumen formation during angiogenesis 
(167,181,182).   
 
Protective Effects 
 Dysfunction within the peripheral microcirculation contributes significantly to pathologic 
conditions but exercise can mitigate the pathologic consequences through its protective actions. 
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Major Depressive Disorder 
Using a chronic mild stress model, Watanasriyakul et al., (183) illustrated the beneficial 
effects of voluntary wheel running in the prairie vole. This study found that exercise trained voles 
had significantly lower depressive- and anxiety-behaviors, along with lower corticosterone levels 
as compared to sedentary voles. Four weeks of swimming exercise reversed UCMS-induced 
depression-like behaviors (184). Vancampfort et al. (185) through meta-analysis found a 
significant negative association between physical activity and suicide ideation (SI) levels. Further, 
“active” people were less likely to have SI but also were protected against SI.      
 
Ischemia 
 Ischemia in any tissue can be deleterious to its function, and therefore, blood flow is of 
utmost importance. Exercise can precondition the heart and skeletal muscles to induce ischemic 
tolerance. The periods of increased blood flow and shear stress stimulate the release of substances 
such as NO and prostacyclin, which not only decrease the permeability of arterial walls to plasma 
lipoproteins, but also attenuate inflammatory processes (186,187).   
 
Inflammation  
 A general risk factor for poor cardiovascular outcomes is chronic inflammation. Diseases 
associated with this type of inflammatory state include MetS, PAD, depression, and CVD. The 
main target of the inflammatory response is the endothelium of both large and small blood vessels 
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alike. This creates endothelial barrier dysfunction, expansion of proinflammatory stimuli, 
enhanced adhesion/leukocyte molecule expression, platelet recruitment, impaired vasomotor 
function, and vascular remodeling (187,188). The proinflammatory response contributes to 
enhanced cell trafficking and to the translocation of large inflammatory molecules into the blood 
vessel due to increase permeability (189). Exercise can reduce the damaging effects of 
inflammation on the endothelium by downregulating transcription of proinflammatory and 
atherogenic genes.        
 
Oxidative Stress 
Endothelium-dependent dilation impairment is caused by increased ROS production by the 
vasculature and circulating immune cells, upregulated angiotensin II and ET-1 production, which 
in turn activate NADPH oxidase and can uncouple eNOS (190). There is a reduction in endothelial-
derived bioavailable NO, which is partially responsible for the diminished responses to Ach or 
increased shear stress. NO and superoxide interact to form peroxynitrite. Peroxynitrite is 
detrimental to NO production because it interacts with the eNOS cofactor, tetrahydrobiopterin, to 
cause eNOS uncoupling (191). The protective effect of exercise acts to decrease ROS production 
and increase eNOS function.   
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Microvascular Rarefaction  
Hypertension, diabetes, and obesity cause the skeletal muscle microcirculation to undergo 
significant degenerative remodeling, known as microvascular rarefaction (Figure 1-6). This results 
from an imbalance of pro- and anti-angiogenic factors, cleavage of vascular growth factor 
receptors by matrix metalloproteinases, oxidant-mediated inactivation of NO, impaired angiogenic 
responses to growth factors, and alterations in adipokine expression (69). However, exercise can 
attenuate microvascular rarefaction by increasing NO bioavailability and decreasing inflammatory 
cytokines such as MCP-1 and IL-1β (69).                
 
 
 
Figure 1-6. Protective effects of exercise. Korthius 2011. 
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Summary and Statement of Aims  
 Previous studies have focused on the causative mechanisms of MetS and chronic stress-
induced depression separately, however, there is a high prevalence of comorbidity between these 
two. The effects of this comorbidity on the peripheral microvasculature are unknown. There is a 
clear association between the vasculopathy present in each disorder and the effect of increased 
oxidative stress on vascular reactivity and MVD. The endothelial functional deficits, as well as the 
loss of MVD, seen in MetS and chronic stress-induced depression are causal to the poor 
cardiovascular outcomes correlated with the disorders. It is important to determine if chronic 
stress-induced depression exacerbates the vascular dysfunction present in MetS. Exercise has been 
shown in many previous studies to augment NO bioavailability, decrease ROS, and improve 
endothelium-dependent dilation response. This raises the question whether exercise can directly 
improve the vascular dysfunction associated with MetS and chronic stress-induced depression, and 
perhaps the exacerbated effects of the comorbidity. Further, exercise may attenuate loss of MVD 
and, in fact, stimulate angiogenesis.   
 Therefore, this dissertation aims to use a valid and reliable model of MetS to examine the 
hypothesis: 1) UCMS will cause peripheral microvascular dysfunction and microvascular 
dysfunction in LZRs similar to that seen in OZRs; 2) OZRs exposed to UCMS will have 
exacerbated peripheral microvascular dysfunction; 3) the peripheral microvascular dysfunction 
and loss of MVD are caused by reduced NO bioavailability and increase in oxidative stress; and 
4) exercise can augment peripheral microvascular dysfunction and rarefaction by decreasing 
oxidative stress and improving endothelium-dependent dilation response.      
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Abstract 
Purpose: The present study examined the effect of unpredictable chronic mild stress (UCMS) on 
peripheral microvessel function in healthy and metabolic syndrome (MetS) rodents, and whether 
exercise training could prevent the vascular dysfunction associated with UCMS.   
Methods: Lean and obese (model of MetS) Zucker rats (LZR; OZR) were exposed to 8 weeks of 
UCMS, exercise (Ex), UCMS+Ex, or control conditions. At the end of the intervention, gracilis 
arterioles (GAs) were isolated and hung in a pressurized myobath to assess endothelium-dependent 
(EDD) and -independent (EID) dilation.  Levels of nitric oxide (NO) and reactive oxygen species 
(ROS) were measured through DAF-FM and DHE staining, respectively.   
Results: Compared to LZR controls, EDD and EID was lower (p=0.0001) in LZR-UCMS. The 
OZR-Ex group had a higher EDD (p=0.0001) and EID (p=0.003), compared to OZR-Controls; 
whereas only a difference in EDD (p=0.01) was noted between LZR-Control and LZR-Ex groups. 
Importantly, EDD and EID were higher in the LZR (p=0.0001; p=0.02) and OZR (p=0.0001; 
p=0.02) UCMS+Ex groups compared to UCMS alone. Lower NO bioavailability and higher ROS 
were noted in the LZR-UCMS group (p=0.0001), but not OZR-UCMS, compared to controls. Ex 
and UCMS-Ex groups had higher NO bioavailability (p=0.0001) compared to control and UCMS 
groups, but ROS levels remained high.  
Conclusions: The comorbidity between UCMS and MetS does not exacerbate the effects of one 
another on GA EDD responses, but does lead to the development of other vasculopathy 
adaptations, which can be partially explained by alterations in NO and ROS production. 
Importantly, exercise training alleviates most of the negative effects of UCMS on GA function. 
Key words: obesity, UCMS, skeletal muscle arteriole, endothelial dysfunction 
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Introduction 
Fifty-six million American adults are diagnosed with the metabolic syndrome (MetS) (1–
4), which significantly increases an individual’s risk of peripheral vascular disease (PVD). Indeed, 
Maksimovic et al. (5) showed that around 60% of patients with PVD also manifested with MetS. 
Our group, and others, have shown in a model of MetS (obese Zucker rat) there is a global 
reduction in vascular-derived nitric oxide (NO) bioavailability, leading to significant peripheral 
vascular dysfunction associated with PVD (6–9).   
Depression is independent risk factor for PVD (10). Previous studies have shown that 
chronic stress is a major contributor to depressive illness and may be the link between depression 
and PVD (11–15). Stress-induced depression causes vascular dysfunction, in part, by impairing 
the bioavailability of dilator metabolites such as NO (16–18). Furthermore, it has been postulated 
that exposure to chronic psychosocial stress is a significant risk factor for the development of 
MetS. Indeed, approximately 43% of MetS patients present with depression (20, 23). Given that 
both MetS and depression result in significant vasculopathies, it remains unknown whether MetS 
exposed to chronic stress results in more severe vasculopathies thereby significantly increasing the 
risk of PVD events (myocardial infarction, heart failure, stroke, and/or limb ischemia).  
Exercise, when used as an intervention, reduces the risk of PVD associated with MetS and 
depression, separately (19,20). Previous studies have shown that chronic exercise training can 
increase the expression of endothelial NO synthase (NOS) and its activity (21–24).  Exercise also 
upregulates antioxidant activity which leads to an attenuation of reactive oxygen species (ROS) 
production, and therefore, decreases oxidative stress (25,26). Through these two mechanisms, 
aerobic exercise can increase NO bioavailability, improving vascular endothelial function (27) and 
perhaps reduce the risk of PVD associated with MetS and depression. However, it is unknown 
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whether chronic exercise can limit or restore the vasculopathies involving MetS exposed to chronic 
stress. 
The current study used the obese (fa/fa) Zucker rat, a translational model of MetS that 
develops significant PVD risk (in the absence of significant atherosclerosis) that can impair 
skeletal muscle perfusion and performance, and its lean controls (LZR) to explore the role of 
unpredictable chronic mild stress (UCMS), exercise (Ex), and a combination of each on peripheral 
microvascular function (8,28). UCMS is a protocol used to induce depressive-like symptoms by 
exposing animal models to daily, mild stressors (29–31). The UCMS protocol is accepted as a 
relevant rodent model of depression that has been shown to reproduce clinical symptoms of 
depression, including anhedonia and increased anxiety-like behavior (32). Our initial hypothesis 
was that: 1) LZRs exposed to UCMS would have peripheral microvascular dysfunction similar to 
that evident in the OZRs controls due to a reduction in NO bioavailability and an increase in ROS 
production; 2) the comorbidity between MetS exposed to UCMS would exacerbate the already 
existing peripheral microvascular dysfunction; and 3) exercise could limit the peripheral 
microvascular dysfunction by decreasing oxidative stress and improving vasodilation associated 
with MetS exposed to chronic stress.    
     
Materials and Methods 
Animals   
 
Male LZR and OZRs (Harlan) arrived at the West Virginia University Health Sciences 
Center (WVUHSC) animal facility at 7-8 weeks of age. After 1 week of acclimation to the local 
environment, LZRs (n = 8 per protocol) and OZRs (n = 8 per protocol) were randomly assigned to 
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a specific protocol group for the subsequent 8-9 weeks including: 1) sedentary controls, 2) UCMS, 
3) exercise (Ex), and 4) a combination of UCMS+Ex, resulting in 8 groups in total. All animals 
were fed standard chow and tap water ad libitum for all experiments. Protocols received prior 
approval from the WVUHSC Animal Care and Use Committee.     
 
UCMS Protocol 
Previous investigators developed the UCMS model for developing depression-like 
behaviors in rodents (212–215). The UCMS model is considered to be the most appropriate rodent 
model for clinical depression, based on its ability to reproduce the development of many clinical 
human depressive symptoms, including anhedonia and learned helplessness (147). 
All rats were singly housed. In UCMS groups, rats were exposed to the following mild 
environmental stressors in randomly chosen sequences for 8 hours each day, 5 days/week, over 
the course of 8 weeks:  
1. Damp bedding – 10 oz. of water was added to each standard cage  
2. Bath – all bedding was removed and ~0.5 inches of water was added to empty cage. Water 
temperature was room temperature, ~24°C  
3. Cage Tilt - cage was tilted to 45 degrees without bedding  
4. Social stress – each rat was switched into a cage of a neighboring rat   
5. No bedding – all bedding was removed from the cage   
6. Alteration of light/dark cycles –turning lights off/on in random increments for scheduled 
period.   
 
Exercise Training Protocol 
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 LZR and OZR underwent 8 weeks of treadmill running, either concurrent with UCMS or 
as a standalone treatment. Animals ran 5 days/week on multi-lane motor driven treadmills set at a 
5% grade. During the first week, animals were acclimatized to the treadmill by running for 20 min, 
then increasing by 10 min/day until sustainable duration of 60 minutes daily was achieved. A 
maximum speed test was performed on each animal and target-running speed was set for 60-70% 
of that maximum. After acclimatization, the first 15 minutes of the total 60 minutes consisted of a 
gradual increase until reaching target-running speed. Rats ran at this speed for the remaining 45 
minutes. Mild electrical stimulus (≤0.3 mA) was used at the rear of the treadmill to discourage rats 
from stopping. There was a 48-hour wash out period between the last Ex bout and the terminal 
surgery at the end of 8-week treatment.    
 
UCMS and Exercise Combination Protocol 
OZRs and LZRs assigned to this group performed treadmill running first thing in the 
morning (8-9am) and then were immediately subjected to the UCMS protocol as described 
previously.   
 
Coat Score  
The rodents coats were evaluated throughout the duration of the 8-week protocol. Each 
week, the rats were weighed and inspected for grooming habits (216). The total cumulative coat 
score was computed by giving an individual score of 0 (clean) or 1 (dirty) to eight different body 
parts (i.e. head, neck, back, forelimbs, stomach, hindlimbs, tail, genitals). 
Circulating Cortisol  
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Corticosterone is a glucocorticoid produced by the adrenal cortex in response to ACTH 
(corticotropic hormone) and is the precursor to aldosterone. Corticosterone is the main 
glucocorticoid in rodents as cortisol is in humans. The production of glucorcorticoids is increased 
by stress. Using a commercially available ELISA Kit (Cayman Chemical, Item #501320) serum 
samples, collected at time of terminal surgery, were examined for corticosterone levels in duplicate 
accordingly to the manufacturer's instructions 
 
Plasma Clinical Markers  
Fasting blood was drawn intravenously from anesthetized rats into lithium-heparin coated 
blood tubes and transported immediately to the laboratory for analysis. Levels of triglycerides 
(TG), total cholesterol (TC), high-density lipoprotein (HDL) were measured by the clinical 
laboratory service at Ruby Memorial Hospital (Morgantown, WV). Blood glucose was measured 
using a commercially available glucometer (FreeStyle, Abbott), and insulin was measured using a 
rat ELISA kit (Cayman Chemical, item #589501). 
 
Isolation of the Gracilis Arteriole 
  After completion of the treatment period and at 17-18 weeks of age, each rat was 
anesthetized with pentobarbital sodium (50 mg/kg ip) and was intubated via the trachea to facilitate 
maintenance of a patent airway. In all rats, a carotid artery and an external jugular vein were 
cannulated for determination of arterial pressure and for infusion of heparin. Under anesthesia, an 
aliquot of blood was drawn from the inferior vena cava to be used for further analysis. 
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With specific attention to the skeletal muscle circulation and its role in the development of 
PVD we selected the gracilis arterioles (GA) to determine the effects of MetS and UCMS on 
peripheral vascular function. Under deep anesthesia, both right and left gracilis arterioles (GA) 
were isolated from their origin in the skeletal muscle of the thigh then placed in cold (4°C) 
physiological salt solution (PSS; in mM: 119 NaCL, 1.17 MgSO4, 1.6 CaCl2, 1.18 NaH2PO4, 24 
NaHCO3, 0.026 EDTA, and 5.5 glucose). Each GA was doubly cannulated in a heated (37°C) 
chamber that allowed perfusion and superfusion of the lumen and exterior of the vessel, 
respectively, with PSS from separate reservoirs. The PSS was equilibrated with a 21% O2-5% 
CO2-74% N2 gas mixture. Vessel diameter was measured using microscopy and an on-screen video 
micrometer.        
 
Measurements of vascular reactivity in isolated GA 
After cannulation, GAs were extended to their in-situ length and equilibrated at 80% of the 
animal’s mean arterial pressure (MAP) to approximate in vivo perfusion pressure.  Active tone at 
the equilibration pressure was calculated as (ΔD/Dmax) x 100, where ΔD is the diameter increase 
from rest in response to Ca2+-free PSS and Dmax is the maximum diameter measured at the 
equilibration pressure in Ca2+-free PSS.   
 After equilibration, the dilator reactivity of GA was assessed in response to increasing 
concentrations (10-10-10-6M) of acetylcholine (ACh) to determine endothelium-dependent dilation 
(EDD) and sodium nitroprusside (SNP, 10-10-10-6M) to determine endothelium-independent 
dilation (EID). Constriction was assessed by exposing the GA to increasing doses of phenylephrine 
(PE, 10-10-10-7M). Vascular responses to ACh were also measured following acute (45-60 min) 
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incubation with nitro-L- arginine methyl ester (L-NAME, a NO synthase inhibitor, Sigma-Aldrich 
N5751) (10-4M) and 4-Hydroxy-TEMPO (TEMPOL, Sigma-Aldrich 176141) (10-4M) to assess 
the contributions of NO and oxidative stress, respectively, to modulation of vascular reactivity.   
 Following the experimental procedures for measuring ex-vivo reactivity, the perfusate and 
superfusate PSS were replaced with Ca2+-free PSS containing the metal chelators EDTA (0.03 
mM) and EGTA (2.0 mM). Vessels were stimulated with 10-7 M (PE) to facilitate Ca2+ release and 
eliminate active tone.  Subsequently, intraluminal pressure within the isolated vessel was altered, 
in 20 mmHg increments, between 0 and 160 mmHg. To ensure that a negative intraluminal 
pressure was not exerted on the vessel, 5 mmHg was used as the “0 mmHg” intraluminal pressure 
point. After 7 mins at each intraluminal pressure, the inner and outer diameters of the passive GA 
were determined.  
 
Measurement of Reactive Oxygen Species 
Dihydroethidium (DHE, Invitrogen D1168) assays were performed on unfixed femoral 
arteries to evaluate superoxide and hydrogen peroxide levels in situ. Femoral artery was used rather 
than GAs because the entire section of isolated GA was used for reactivity. Femoral arteries were 
placed in individual wells of a 96 well plate containing 200μl of HEPES buffer. Femoral artery 
was incubated in control/drug treatment for 30 minutes at 37°C. Following incubation, 2μl of stock 
DHE solution was added to each well to a concentration of 10μM and incubated at 37°C for another 
30 minutes. After completion of DHE incubation, arteries were washed in HEPES buffer, placed 
separately in Optimal Cutting Temperature compound (OCT, Fisher Healthcare™ Tissue-Plus™ 
O.C.T Compound), and flash frozen in liquid nitrogen to be stored at -80°C.  DHE OCT blocks 
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were then cut into 8μm slices using a cryostat at -22°C and transferred to charged slides 
(Fisherbrand® Superfrost® plus microscope slides) and stained/mounted with DAPI mounting 
media (VECTORSHEILD antifade mounting media with DAPI, Vector laboratories). Four slices 
per animal were imaged with an EVOS fluorescent microscope (Invitrogen EVOS FL Auto Cell 
Imaging System) and then analyzed in ImageJ as fluorescent density/nucleus.  
 
Measurement of NO Bioavailability 
Aortic NO levels were measured by 4-Amino-5-Methylamino-2′,7′- Difluorofluorescein 
Diacetate (DAF-FM-DA, Invitrogen) according to manufacturer's instructions. As stated 
previously, aortas were used because GA reactivity required the entire section of vessel. 3mm 
aortic rings were placed in individual wells of a 96 well plate containing 200μl of HEPES buffer 
supplemented with L-Arginine (100μM, MP Biomedical Inc. 100736).  L-NAME was used as a 
negative control. After 30-minutes incubation with treatment, DAF-FM 10μM was added to each 
well and the vessel was stimulated with Acetyl-β-methylcholine chloride (methacholine (MCh), 
1X10-6, Sigma-Aldrich A2251). After 10 minutes, the aorta was removed and the conditioned 
solution was read in a plate reader excitation/emission at 495/515nm wavelength (BioTek Synergy 
HT). Fluorescence was normalized to aorta length and the L-NAME value to account for the 
reaction of the DAF assay with other molecules (i.e., hydrogen peroxide). 
 
Data and Statistical Analyses 
Data are presented as mean ± SD. Normality was evaluated by the Kolmogorov–Smirnov 
test. The maximal reactivity or the remodeling of the GA due to the experimental conditions were 
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analyzed by a multifactorial analysis of variance (ANOVA) [ i.e., species (i.e., LZR vs. OZR), and 
experimental condition (i.e., Control, UCMS, Ex, and UCMS+Ex)] with an interaction term 
(species-by-group), and a Tukey post-hoc test was performed to determine differences between 
groups. The effects of TEMPOL and L-NAME on the maximal dilation of the GA was examined 
with a repeated measures ANOVA. Clinical characteristics between the animals were compared 
with a One-Way ANOVA with Tukey post-hoc test, as appropriate. DHE, was examined using 
Kruskal Wallis test, with within group comparisons examined using the Mann-Whitney test. In all 
cases, p<0.05 was taken to reflect statistical significance. 
 
Results 
Animal Characteristics  
The baseline characteristics of the animals used in the present study are summarized in 
Table 2-1. In comparison to LZR and OZR controls, the intervention groups had a lower body 
mass at the end of the intervention. Mean arterial pressure did not differ between UCMS or Ex 
groups.  Higher fasting glucose concentrations were noted in the LZR and OZR UCMS group 
compared to their respective controls. Further, glucose concentrations were lower in the OZR-Ex 
group, but higher in the OZR-UCMS+Ex compared to OZR-controls. Markers and symptoms of 
stress were elevated in both LZRs and OZRs using the UCMS protocol as seen by an increase in 
corticosterone and coat scores in both LZR and OZR-UCMS, and UCMS+Ex groups compared to 
controls. Also, there was an increase in adrenal weights with UCMS in LZRs, from 16.7g to 25.1g 
(p=0.0001) and in OZRs, from 27.2g to 32.7g (p=0.0001) (data not shown). Adrenal weight did 
not significantly change in LZR- or OZR-UCMS+Ex as compared to their respective controls.     
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Effects of Experimental Conditions on GA Reactivity  
Figure 2-1 illustrates the EDD, EID, and constriction responses of the GA for each 
treatment group. After 8 weeks of UCMS in LZRs, there was a significant impairment in EDD 
(73%, p=0.0001) compared to LZR-Controls. EDD was higher in LZR-Ex (41%, p=0.009) 
compared to LZR-Controls, and EDD was also higher in the LZR-UCMS+Ex (209%, p=0.0001) 
vs. LZR-UCMS. Importantly, now EDD in the LZR-UCMS+Ex group did not statistically differ 
compared to LZR-Control. In the OZR groups, UCMS did not attenuate EDD further (Fig 2-1A); 
however, in the OZR-Ex group, EDD was higher (141%, p=0.0001) compared to OZR-Controls. 
When Ex was combined with UCMS, the EDD was higher (174%, p=0.0001) vs. OZR-UCMS, 
and EDD in the OZR-UCMS+Ex group was also higher (83%, p=0.02) than OZR-Controls (Fig. 
2-1A). Of note, there was a significant (p=0.0006) species (LZR vs. OZR) by group (Con, UCMS, 
Ex, UCMS+Ex) interaction for the GA EDD response.  
 Next, we examined EID of the GA, and found that EID was lower (53%, p=0.001) in LZR-
UCMS compared to LZR-Controls (Fig. 2-1B), but no differences were noted in EID between 
LZR-Ex and LZR-Control groups. Importantly, the concurrent exposure of LZR to UCMS and Ex 
resulted in a higher EID (56%, p=0.02) compared to LZR-UCMS, and made EID similar between 
LZR-UCMS+Ex and LZR-Control groups. As for the OZR groups, no significant differences in 
EID were noted between OZR-UCMS and OZR-Controls; however, EID was higher in the OZR-
Ex (88%, p=0.003) vs. OZR-Controls (Fig. 2-1B). Further, EID in OZR-UCMS+Ex was higher 
(17%, p=0.02) compared to OZR-UCMS (Fig. 2-1B). We also noted a close to significant 
(p=0.054) species-by-group interaction for the GA EID response.  
 The GA constriction response was evaluated by stimulating the GA with increasing doses 
of PE (Fig. 2-1C). In LZR, UCMS resulted in a smaller constriction response (57%, p=0.002) 
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compared to LZR-Controls. The GA constriction response was similar between LZR-Ex, LZR- 
UCMS+Ex, and LZR-Control groups. In the OZR, the GA constriction response was similar 
between all groups. As such, a significant (p=0.001) species-by-group interaction was noted for 
the GA constriction response. 
 
Effect of Acute TEMPOL or L-NAME on GA 
To examine whether the impairment in the GA EDD was a reflection of increased oxidative 
stress and reduced NO bioavailability, the GA was acutely incubated with TEMPOL and L-NAME 
(Fig. 2-2). Of note, all comparisons here are compared to within the experimental group without 
the TEMPOL, or L-NAME incubation (i.e., LZR control-TEMPOL vs. LZR control). Acute 
TEMPOL incubation did not significantly impact EDD in LZR-Control, LZR+Ex, and LZR-
UCMS+Ex (Fig. 2-2A); however, in the LZR-UCMS group, TEMPOL significantly increased 
EDD (81%, p=0.009), suggesting a role of oxidative stress on the impaired EDD with UCMS in 
LZRs. Acute TEMPOL incubation significantly increased EDD in OZR-Control (76%, p=0.01) 
and OZR-UCMS (149%, p=0.03) (Fig. 2-2B). Neither OZR-Ex nor OZR-UCMS+Ex had any 
improvements in EDD with acute TEMPOL incubation. A significant (p=0.0012) species-by-
group interaction was noted for the EDD-TEMPOL response. 
As with TEMPOL, we also incubated the GA with L-NAME to examine the role of NO. 
Acute L-NAME incubation severely blunted the EDD in LZR-Control (75%, p=0.0001), LZR-Ex 
(76%, p=0.0001), and LZR-UCMS+Ex (64%, p=0.0001) groups but had minimal effect on EDD 
in the LZR-UCMS group (9%, p=0.99) (Fig. 2-2C).  In the OZR groups, acute L-NAME 
incubation only significantly blunted EDD in OZR-Ex (71%, p=0.0001) and OZR-UCMS+Ex 
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(65%, p=0.0001), with no significant effects in the OZR-Controls, and OZR-UCMS groups (Fig. 
2-2D). We also noted a significant (p=0.0001) species by group interaction for the EDD-L-NAME 
response. 
 
Effects of Experimental Conditions on GA Remodeling  
Following assessment of vessel reactivity in our experimental groups, we then examined, 
under passive conditions, the GA remodeling. There were minimal changes in ID, OD, and WT in 
the LZR-UCMS vs. LZR-Control groups (Table 2-2); however, an increase in the ß-slope of the 
GA stress-strain relationship (p=0.05) was noted in LZR-UCMS vs. LZR-Control. In contrast, no 
differences were noted between LZR-Ex, LZR-UCMS+Ex, or LZR-Control groups for ID, OD, 
WT, or ß-slope, suggesting that Ex limited the increased GA stiffness noted with UCMS alone in 
LZRs. As for the effects of the experimental conditions in OZR, we noted a significantly lower ID 
and OD in OZR-UCMS vs. OZR-Controls (p=0.01), and as such WT did not differ between OZR-
UCMS vs. OZR-Controls (Table 2-2). Further, an increase in the ß-slope of the GA stress-strain 
relationship (p=0.01) was noted in the OZR-UCMS vs. OZR-Controls (Table 2-2). No significant 
differences were noted in ID, OD, WT, and the ß-slope of the stress-strain relationship between 
OZR-Ex and OZR-Control groups. However, when Ex was combined with UCMS, the ID and OD 
were reduced (16%-18%, p<0.05) and the ß-slope was increased (80%, p=0.001) in OZR-
UCMS+Ex vs. OZR-Controls, as such the effects of UCMS+Ex on GA remodeling was similar to 
that noted with UCMS alone in OZRs (Table 2-2). No significant species-by-group interactions 
were identified for GA remodeling. 
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NO and ROS Levels                
The improvement in EDD with acute TEMPOL or Ex suggested that the endothelial 
dysfunction in MetS with and without UCMS was in part, mediated by changes in ROS and NO 
levels. We therefore, examined NO levels in the aorta as determined by DAF-FM diacetate assay. 
NO bioavailability was lower in LZR-UCMS (68%, p=0.0001) compared to LZR-Controls, but 
higher in LZR-Ex (15%, p=0.001) vs. LZR-Control, and NO bioavailability was higher (25%, 
p=0.0001) in the LZR-UCMS+Ex vs. LZR-UCMS group. As for the OZR groups, NO 
bioavailability was similar between OZR-UCMS and OZR-Controls; however, NO bioavailability 
was higher (146%, p=0.0001) in OZR-Ex vs. OZR-Controls, and slightly higher (14%, p=0.057) 
in OZR-UCMS+Ex vs. OZR-UCMS group (Fig. 2-3A).  
Figure 2-3B illustrates ROS levels in the femoral artery. Levels of ROS were higher in 
LZR-UCMS (99%, p=0.0001), LZR-Ex (99%, p=0.003), and LZR-UCMS+Ex (100%, p=0.0001) 
vs. LZR-Controls. Further, the ROS levels were higher in LZR-UCMS+Ex vs. LZR-Ex (130%, 
p=0.0001), and LZR-UCMS (101%, p=0.04). In the OZR groups, as with NO bioavailability, ROS 
levels did not differ between OZR-UCMS and OZR-Controls. No differences in ROS levels were 
noted between the OZR-UCMS+Ex vs. OZR-Controls, or OZR-UCMS groups. 
 
Discussion  
The present study is the first to look at the comorbidity between MetS undergoing chronic 
stress and the effects of Ex on limiting the peripheral vascular effects associated MetS and UCMS. 
Our results suggest that: 1) exposure to UCMS in LZR resulted in vascular pathologies similar to 
that evidence in OZR-Controls without the major changes in body mass, glucose or lipid profiles; 
74 
 
2) exposure to UCMS in OZR did not further affect EDD; and 3) Ex combined with UCMS 
improved peripheral microvascular dysfunction associated with UCMS. 
 
The Impact of UCMS on the GA 
Chronic psychosocial stress has been proposed as a risk factor for the development of the 
MetS (35,36). Thus, we were interested in understanding to what extent exposing a healthy rat 
(LZR) to the UCMS protocol would result in a MetS phenotype. The UCMS protocol resulted in 
some mild changes in fasting glucose, with a slight, but non-significant increase in triglycerides 
and MAP, and an actual reduction in BM in the LZR. Thus, one cannot say that the LZR now 
resembles a MetS phenotype based on the classification of MetS (i.e., BM, blood pressure, glucose, 
cholesterol); however, the LZR established substantial peripheral microvascular dysfunction that 
would represent the vasculopathies noted in an OZR. Indeed, the UCMS protocol severely blunted 
EDD and EID in LZR-Control. We have shown that UCMS significantly decreased NO and 
increased ROS production, which is the most likely cause of the impairment of EDD in LZRs. 
These results were also supported by the fact that acute incubation with the ROS scavenger, 
TEMPOL, improved EDD in LZR-UCMS, likely allowing NO levels to rise. Further, we also 
noted an increased production of ROS and a corresponding decrease in NO-bioavailability in the 
LZR-UCMS group. The UCMS-induced impairment of EID found in the present study is contrary 
to a similar study using UCMS in mice (37), but is in concurrence with a study using chronic social 
isolation in prairie voles (38). Factors that may have contributed to the smooth muscle damage 
include dysfunction of certain secondary messengers and their receptors, and increased 
cyclooxygenase signaling. One such secondary messenger is soluble guanylyl cyclase, which can 
be inhibited by increased levels of ROS. Inhibition of cyclic adenosine monophosphate expression 
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by overproduction of cortisol could also influence smooth muscle function (39–41). Furthermore, 
an increase in thromboxane production can lead to smooth muscle cell dysfunction, thus creating 
chronic vasoconstriction (42,43). However, further research is needed to address the potential 
reasons for the impaired EID with UCMS. 
Previous studies by our group and others have examined the effects of MetS and UCMS 
on microvascular function separately (5,6,11,37,44,45) but to what extent the development of 
vascular pathologies occurs with the progression of MetS undergoing UCMS remained unclear.  
The condition of MetS already has significant microvascular dysfunction, therefore, it was 
important to examine the vascular pathologies during comorbidity. The UCMS protocol did not 
have a significant impact on EDD or EID in the OZR. The lack of UCMS effect on EDD in OZR 
may be due to the fact OZR-Controls demonstrate elevated ROS levels, and thus diminished 
bioavailable NO, unlike LZR-Control. Our group has previously shown in the GA that NO levels 
in OZR-Control are substantially lower than LZR-Control, as well as in other models of disease 
states such as hypertension, high-fructose diet, and high-salt diet (9). Therefore, the severity of 
impairment in OZRs may make them less susceptible to the effects of UCMS than in LZRs. 
TEMPOL increased EDD in OZR-Control and OZR-UCMS, suggesting that ROS scavenging can 
recover the reduction in NO caused by UCMS and MetS. These data were confirmed by the effect 
of acute incubation with L-NAME, which blunted dilation response in the Ex and UCMS+Ex 
groups.  
There are various other mechanisms that could be affecting the microvasculature during 
the comorbidity between UCMS and MetS.  For example, with chronic stress and depression there 
is an increase in cortisol/corticosterone levels as we have seen here in our LZR- and OZR-UCMS 
groups. Chronically elevated cortisol results in overproduction of angiotensin II (Ang II), which 
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causes vasoconstriction. Ang II has also been shown to cause an increase in endothelim-1, 
thromboxane, and ROS through activation of AT1 type receptors (46). Thus, the increase in 
circulating Ang II in vivo causes changes in the smooth muscle and endothelium, possible 
contributing to the impairment in EDD seen in vitro in LZR- and OZR-UCMS groups.  
Peripheral microvascular wall dimensions were not affected by UCMS in LZRs but the 
stress-strain relationship was shifted to the left, suggesting an increase in stiffness. This response 
could reflect changes in the collagen deposition and elastin fractionation in the LZR GA (47,48).  
In contrast, UCMS significantly decreased both inner and outer diameters in OZRs as compared 
to their controls, indicating eutrophic inward remodeling.  Eutrophic inward remodeling could be 
caused by repositioning of vascular smooth muscle cells to adapt to the chronic circumferential 
stress (49). OZR-UCMS also had a significant leftward shift in the stress-strain relationship, 
implying a stiffening of the vessels.  Physical inactivity, a by-product of depression and a cause of 
MetS, produces oxidative stress and inflammation (50). Therefore, Ex is the logical intervention 
to augment the deleterious effects of MetS and depression.  
 
Exercise Can Improve Aspects of the Comorbidity of MetS and UCMS    
    Exercise increased LZR EDD but Ex had a much greater effect on OZR EDD response 
overall. Exercise significantly enhanced NO bioavailability in LZRs and OZRs, which could 
explain why there was a greater improvement in dilation in LZR- and OZR-Ex. An earlier study 
found NO production and arginine conversion (indicating eNOS activity) were both increased with 
Ex (20). Following Ex, EDD was unaffected by the ROS levels as supported by the lack of 
TEMPOL effect in both LZR- and OZR-Ex groups. The specific cause of the elevation of ROS 
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levels is unclear given Ex has been shown to have antioxidant effects itself (25,26). However, 
corticosterone levels were elevated in the Ex and UCMS+Ex groups vs. the controls which may, 
in part, reflect the slight stress induced by use of the forced treadmill Ex protocol. It has been 
shown that glucocorticoids can increase ROS directly, including superoxide, hydrogen peroxide, 
and peroxynitrite (12). Given that DHE can interact with these oxidants, it could be speculated the 
higher ROS levels seen in LZR-Ex and UCMS+Ex are a byproduct of increased corticosterone. 
The fact that in Ex and UCMS+Ex EDD was improved despite elevated corticosterone levels, 
suggests EDD augmentation was likely mediated from non-corticosterone pathways. L-NAME 
blunted maximum dilation back down to LZR- and OZR-Control+LNAME values, suggesting the 
Ex augmentation of EDD may be solely through a NO-dependent pathway. The expression and 
function of eNOS is upregulated after Ex training due to increased shear stress (23,51), thus could 
explain why EDD in LZR- and OZR-Ex was improved in the skeletal muscle arterioles. Ex did not 
change EID response in LZRs or OZRs as compared to their respective controls, which was 
supported by a previous study from our group also showing no change in EID in LZRs and OZRs 
(20).  
      Ex did not result in GA structure remodeling in either the LZRs or OZRs, but Ex was able 
to prevent the level of impairment in EDD seen in LZR- and OZR-UCMS. Perhaps the increase in 
NO bioavailability in the UCMS+Ex groups, relative to the UCMS groups, limited the GA 
structure remodeling. LZR- and OZR-UCMS+Ex did not show an increase in EDD of the GA 
when incubated with TEMPOL as compared to their respective Control+TEMPOL values, which 
would suggest that TEMPOL did not have an additive effect when paired with exercise. EID was 
also increased with exercise in LZR- and OZR-UCMS+Ex. Furthermore, in the LZR, the 
combination of Ex with UCMS prevented the leftward shift (and increase GA stiffness) in the 
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stress strain relationship as evident in the LZR-UCMS group, suggesting a global improvement in 
microvascular function (i.e., EDD, EID with reduced arterial stiffness). However, the combination 
of Ex with UCMS in OZR was unable to prevent the increase in GA arterial stiffness. Perhaps here 
the comorbidity of MetS and UCMS was too much of stressful stimulus for 8 weeks of Ex to 
prevent. Further, research is needed to identify whether longer periods of Ex or a combination of 
Ex with ‘destiffening’ agents (i.e., ALT-711) could be used to prevent the increase in arterial 
stiffness with UCMS in the OZR.  
 
Limitations  
The present study is not without limitations. We realize the limitation associated with 
measuring tissue superoxide levels by fluorescence-based assessment of DHE oxidation. While 
our excitation/emission gating does detect signals produced by oxidation products that may 
originate from reactions independent of superoxides, the spectral overlap does not exclude 
considerable contributions from 2-hydroxyethidium (2-OH-E+), the superoxide-specific oxidation 
product of DHE (232). The possible explanation for the higher ROS levels in LZR-Ex and LZR-
UCMS+Ex is the generation of hydrogen peroxide by Ex. Hydrogen peroxide has been shown to 
be a vasodilator and produced during Ex (233). Further, it was interesting to note that 
corticosterone levels were elevated in the Ex and UCMS+Ex groups vs. the controls, which could 
also have contributed to more hydrogen peroxide production, thus increasing fluorescence 
intensity in the Ex and UCMS+Ex groups. Future research should use HPLC to look for superoxide 
and 2-OH-E+ levels to obtain a more quantitative indicator of these products.  
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Another limitation that may, in part, affect the translational relevance of our study was that 
we deployed a forced treadmill running protocol as opposed to voluntary wheel running, which in 
itself can cause stress. However, given the sedentary nature of the OZR, we wanted to ensure that 
all rats were exposed to a similar Ex stimulus. In addition, given the size of the OZRs (by 12-15 
weeks), it would be difficult for them to fit into a running wheel. Thus, although voluntary Ex 
would be more translationally relevant, unfortunately, in the OZR rats forced treadmill exercise 
was the most feasible option, we believe the benefits of forced Ex outweighed the stress the rats 
might undergo. 
 
Conclusions 
The data presented here shows that the chronic exposure to stressful conditions in healthy 
rats leads to substantial vasculopathies similar to that in an OZR. Further, the comorbidity between 
chronic stress and MetS, does not exacerbate the effects of one another on skeletal muscle arteriole 
EDD response. It does, however, lead to the development of other vasculopathy adaptations in 
relation to constriction response. We have found that Ex can improve these pathological 
maladaptations and that the NO pathway has the potential to be a therapeutic target in clinical 
settings.   
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  Table 2-1.  Baseline characteristics of animal groups. 
Con, control; UCMS, Unpredictable Mild Chronic Stress; Ex, exercise; BM, body mass; MAP, mean arterial 
pressure; TG, triglycerides; TC, total cholesterol. *p<0.05 vs. control, ^p<0.05 vs. Ex. Mean ± SD. n=6-8 per 
group.  
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  Table 2-2. Gracilis arteriole remodeling due to MetS and UCMS in the GA.  
Con, control; UCMS, Unpredictable Mild Chronic Stress; Ex, exercise; ID, inner GA diameter; OD, 
outer GA diameter; WT, wall thickness. *p<0.05 vs. control, #p<0.05 vs. UCMS. Mean ± SD. n=6-8 per 
group.  
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Figure 2-1. The effects of UCMS and Ex on GA reactivity. A) Assessment of 
endothelium-dependent dilation (EDD) to a maximal does of Ach (10-6M); B) 
endothelium-independent dilation (EID) to a maximal does of SNP (10-6M); and C) 
GA constriction to a maximal does of PE (10-7M). n = 6-8/group. Mean ± SD. *p<0.05 
vs. control, #p<0.05 vs. UCMS, ^p<0.05 vs. Ex, °p<0.05 vs. matched treatment group 
in opposite species (i.e., LZR vs. OZR), ‡p<0.05 species (LZR vs. OZR) by group 
(Con, UCMS, Ex, UCMS+Ex) interaction. Con=control, UCMS=Unpredictable Mild 
Chronic Stress, Ex=exercise.  
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Figure 2-2. The effects of acute TEMPOL or L-NAME incubation on GA 
reactivity. The effects of acute TEMPOL incubation on EDD reactivity in LZR (A) 
and OZR (B). The effects of acute L-NAME incubation on EDD reactivity in LZR 
(C) and OZR (D).  n = 6-8/group. Mean ± SD. *p<0.01 vs. control, #p<0.01 vs. 
UCMS, ^p<0.05 vs. exercise, +p<0.05 within group comparison for change in 
TEMPOL or L-NAME. ‡p<0.05 species (LZR vs. OZR) by group (Con, UCMS, Ex, 
UCMS+Ex) interaction. Con=control, UCMS=Unpredictable Mild Chronic Stress, 
Ex=exercise. 
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Figure 2-3.  The effects of UCMS and Ex on NO and ROS levels. A) NO levels in the aorta as 
determined by DAF-FM diacetate assay; and B) DHE staining indicating ROS levels in the aortas 
of each group. Mean ± SD. *p<0.05 vs. control, #p<0.05 vs. UCMS, ^ p<0.05 vs. exercise, °p<0.05 
vs. matched treatment group in opposite species. ‡p<0.05 species (LZR vs. OZR) by group (Con, 
UCMS, Ex, UCMS+Ex) interaction. Con=control, UCMS=Unpredictable Mild Chronic Stress, 
Ex=exercise. 
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Figure S-1. The Effect of UCMS and Exercise on EDD in LZRs and OZRs. A) Assessment of 
endothelium-dependent dilation by exposure to increasing doses of Ach (10-10-10-6M) in control 
vs. UCMS, B) in control vs. exercise, C) in control vs. UCMS+Exercise. n = 6-8/group. Mean ± 
SEM.  *p<0.01 vs. control, #p<0.01 vs. UCMS, ^ p<0.01 vs. exercise.   
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Figure S-2. The Effect of UCMS and Exercise on EID in LZRs and OZRs. A) Assessment of 
endothelium-independent dilation by exposure to increasing doses of SNP (10-10-10-6M) in 
control vs. UCMS, B) in control vs. exercise, C) in control vs. UCMS+Exercise. n = 6-8/group. 
Mean ± SEM.  *p<0.01 vs. control, #p<0.01 vs. UCMS, ^ p<0.01 vs. exercise.   
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Figure S-2. The Effect of UCMS and Exercise on Constriction in LZRs and OZRs. A) 
Assessment of endothelium-independent dilation by exposure to increasing doses of PE (10-10-
10-7M) in control vs. UCMS, B) in control vs. exercise, C) in control vs. UCMS+Exercise. n = 
6-8/group. Mean ± SEM.  *p<0.01 vs. control, #p<0.01 vs. UCMS, ^ p<0.01 vs. exercise.   
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Introduction 
 
Endothelial cells play a primary role in maintaining microvascular function in the brain. 
These cells produce metabolic factors in response to stimuli and induce vasodilation or 
constriction. Proper endothelial function is essential to blood perfusion in any tissue, but especially 
in the most perfused organ in the body, the brain (1). In the cerebral vasculature, pericytes are 
adjacent to capillaries and share a common basement membrane with endothelial cells. Pericytes 
are important in cerebral capillary function by regulating cerebral blood flow, upregulating tight 
junction proteins, contributing to ion and water homeostasis, and interfacing directly with neurons 
(2–5). Further, pericytes also have several roles in regards to the cerebrovasculature such as 
contributing to the stability of the vessel, release of growth factors and matrix important for 
microvascular permeability, remodeling, and angiogenesis (6). 
Metabolic syndrome (MetS), which is a collection of risk factors including hypertension, 
dyslipidemia, abdominal obesity, and high blood sugar (7), affects 56 million American adults (8). 
Through the collaborative deleterious effects of the MetS pathophysiologies, the vascular system 
is severely impacted including impairments in endothelial function and microvessel density. MetS 
has been found to reduce capillary-to-fiber ratio and microvessel density (MVD) in both the 
skeletal muscle and heart (9). In addition, MetS has also been shown to decrease functional brain 
capillary density and microvascular blood perfusion (10). A reduction of MVD in any vascular 
bed can cause disruption in patterns of blood flow and increased peripheral vascular resistance 
leading to an elevated risk of poor cardiovascular outcomes (11–13).      
It has been postulated that exposure to chronic psychosocial stress is a significant risk 
factor for the development of MetS (14–16). Indeed, approximately 43% of MetS patients present 
with depression (17). Unpredictable Chronic Mild Stress (UCMS) is a validated animal model 
101 
 
using chronic stress to induce depressive symptoms (18,19). Most studies that use this model have 
documented physiological changes in the brains of rodents, mainly reflecting an elevated 
physiological stress response (19). An elevated stress response can lead to vascular impairments 
due to increased cortisol levels and oxidative stress (20–22). Isingrini et al. (23), illustrated an 
overall decrease in endothelium-dependent dilation response of the aorta in UCMS-exposed mice 
as a result of decreased nitric oxide (NO) bioavailability. Although not much is known about the 
direct effect of chronic stress on cerebral microvascular rarefaction, an increase in cortisol has 
been shown to inhibit endothelial cell proliferation and induce apoptosis in pericytes in the brain 
(21,24). As with MetS, the chronic stress-induced loss in MVD can significantly increase an 
individual’s risk of stroke or myocardial infarction (11,25).  
Exercise is often used to reduce the risk factors of MetS through lifestyle changes and has 
also proven to have beneficial effects on depression (26–30) . One of these health benefits is an 
augmentation of microvascular rarefaction in pathological states. In a study by Machado et al. (31), 
two and a half hours of exercise per week resulted in an increase in capillary density in skeletal 
muscle, but only ninety minutes per week was required to reverse the microvascular rarefaction 
caused by a high fat diet in the left ventricle. Four weeks of aerobic exercise has been shown to 
increase both capillary density and surface area within the white matter of the brain (32).  Further, 
previous studies have found that exercise by downregulating TNF-α and IL-1β could perhaps 
protect pericytes from apoptosis and enhance angiogenesis through upregulation of VEGF (33). 
These results suggest exercise could be a candidate therapeutic in individuals with comorbid MetS 
and depression to improve MVD.  
 The present study used the obese Zucker rat (OZR), an accepted, translational model of 
MetS, and induced depressive symptoms in these rats using the UCMS protocol. We hypothesized 
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that: 1) cerebral MVD, along with pericyte number, would be reduced in rats exposed to UCMS; 
2) cerebral MVD and pericytes would be increased with exercise; 3) exercise could mitigate the 
loss of cerebral MVD caused by the comorbidity between MetS and depression; and 4) the increase 
in MVD and number of pericytes would be reflected by an increase in VEGF and decrease in 
oxidative stress markers.        
 
Materials and Methods 
Animals   
Male LZR and OZRs (Harlan) arrived at the West Virginia University Health Sciences 
Center (WVUHSC) animal facility at 7-8 weeks of age. After 1 week of acclimation to the local 
environment, LZRs (n = 8 per protocol) and OZRs (n = 8 per protocol) were randomly assigned to 
sedentary control or UCMS for the subsequent 8-9 weeks. All animals were fed standard chow 
and tap water ad libitum for all experiments. Protocols received prior approval from the WVUHSC 
Animal Care and Use Committee.     
 
UCMS Protocol 
Previous investigators developed the UCMS model for developing depression-like 
behaviors in rodents (34–37). The UCMS model is considered to be the most appropriate rodent 
model for clinical depression, based on its ability to reproduce the development of many clinical 
human depressive symptoms, including anhedonia and learned helplessness (19). 
All rats were singly housed. In UCMS groups, rats were exposed to the following mild 
environmental stressors in randomly chosen sequences for 8 hours each day, 5 days/week, over 
the course of 8 weeks:  
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7. Damp bedding – 10 oz. of water was added to each standard cage  
8. Bath – all bedding was removed and ~0.5 inches of water was added to empty cage. Water 
temperature was room temperature, ~24°C  
9. Cage Tilt - cage was tilted to 45 degrees without bedding  
10. Social stress – each rat was switched into a cage of a neighboring rat   
11. No bedding – all bedding was removed from the cage   
12. Alteration of light/dark cycles –turning lights off/on in random increments for scheduled 
period.   
 
Coat Score 
Coat score evaluation was done for every group throughout the duration of the 8-week 
protocol. Each week, the rats were weighed and inspected for grooming habits (38). The total 
cumulative score was computed by giving an individual score of 0 (clean) or 1 (dirty) to eight 
different body parts (i.e. head, neck, back, forelimbs, stomach, hindlimbs, tail, genitals). 
 
Surgical Procedures  
After completion of the treatment period and at 17-18 weeks of age, each rat was 
anesthetized with pentobarbital sodium (50 mg/kg ip) and was intubated via the trachea to facilitate 
maintenance of a patent airway. In all rats, a carotid artery and an external jugular vein were 
cannulated for determination of arterial pressure and for infusion of heparin. Under anesthesia, an 
aliquot of blood was drawn from the inferior vena cava. Tissues of interest were isolated from each 
animal for further analysis.   
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Immunohistochemistry 
After rats were euthanized, surface cerebral blood vessels were removed for further 
analysis and the brain was placed in a matrix to cut 2 mm coronal slices. These slices were then 
flash-frozen in liquid nitrogen-cooled isopentane and store at -80°C for later use. Brain slices were 
sectioned into 8 µm slices using a cryostat at -24°C and transferred to positively charged 
microscope slides (Fisherbrand® Superfrost® plus microscope slides).   
Cerebral microvessel and capillary density was evaluated by fluorescence 
immunohistochemistry using purified rat anti-mouse CD31 antibody (BD Biosciences, San Diego, 
CA) and rat anti-rabbit desmin antibody (Abcam, Cambridge, MA). Briefly, brain sections were 
fixed with 10% formalin, permeabilized with 0.2% Triton X-100, and blocked with blocking 
solution (5% BSA in PBS) and then incubated with anti-CD31 (1:100) and anti-desmin (1:200) 
overnight in a humidified chamber at 4°C. Following three washes with PBS, cells were incubated 
with AlexaFluor 555-conjugated anti-mouse IgG (1:1000; Invitrogen) and AlexaFluor 488-
conjugated anti-rabbit IgG (1:1000; Invitrogen) for 2 h at room temperature in a humidified 
chamber. After a final wash with PBS, cover glass was mounted with hard-set DAPI medium 
(Vector Laboratories, Burlingame, CA). Negative control was performed with the same procedure 
without primary antibody. Images were obtained with an epifluorescence microscope (EVOS, 
ThermoFisher Scientific). The microvessel density of co-labeled cells were analyzed in 6 regions 
of interest (3 in cortex and 3 in striatum) in the MCA territory using ImageJ, as described 
previously (39). 
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Real-Time Quantitative PCR 
RNA was extracted with the Direct-zol™ RNA MiniPrep Kit (Zymo Research) and reverse 
transcription was done using the QuantiTect Reverse Transcription Kit (Qiagen), according to 
manufacturer’s protocols. QuantiTect primers (Qiagen) were used including: catalase, SOD, GSR, 
CD68, Nox2, VEGF, and TSP-1. Quantitative RT-PCR analysis was performed in duplicates for 
each sample using QuantiTect SYBR Green master mix (Qiagen) according to manufacturer’s 
instructions and on the Roto-Gene thermocycler (Qiagen). Rat 18S rRNA was used as a 
housekeeping gene to normalize expression of gene of interest depending on the experiment. 
Relative expression was calculated by the comparative CT (2-ΔΔCt values indicate fold change of 
the gene of interest in the samples relative to a selected control, 2-ΔCt values indicate relative 
expression of gene interest between samples normalized to 18S.  
 
Determination of VEGF concentration 
 Brain tissue was homogenized using a bead mill and protein concentration was assessed 
by Bradford assay (DC Protein Assay, BioRad). Brain VEGF concentration was then determined 
with a commercially available rat VEGF-A sandwich-based ELISA kit (RayBiotech).  
 
 
Determination of TSP-1 concentration   
 As with the VEGF ELISA, brain tissue was homogenized using a bead mill and protein 
concentration was assessed by Bradford assay (DC Protein Assay, BioRad). TSP-1 concentrations 
were determined as part of a rat inflammation V-plex panel ELISA (MesoScale Discovery).  
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Statistical Analysis  
Data are presented as mean ± SEM. CD31+Desmin IHC was analyzed by a two-way 
analysis of variance (ANOVA), with a Tukey’s post-hoc. RT-PCR was analyzed by a one-way 
repeated-measured ANOVA, with a Greenhouse-Geisser correction was performed to determine 
differences between groups. Protein levels were analyzed by a two-way analysis of variance 
(ANOVA), with a Tukey’s post-hoc. In all cases, p<0.05 was taken to reflect statistical significance.  
 
Results  
Figure 3-1 represents the immunohistochemistry (IHC) of the endothelial cell marker, 
CD31, and its co-labeling with desmin, a pericyte marker, in the cortex and striatum of the brain. 
The co-labeled cells are considered to be angiogenic microvessels. In LZRs, UCMS decreased the 
amount of CD31+Desmin+ cells within the cortex as compared to controls (37%, p<0.01). 
However, UCMS did not affect MVD in OZR-UCMS. Exercise had higher MVD as compared to 
LZR Controls (18%, p<0.05), and in OZR-Ex vs. their controls (79%, p<0.05). In fact, when 
exercise was paired with UCMS, exercise improved MVD to control levels in LZRs (38%, p<0.01) 
and higher than control levels in OZRs (74%, p<0.01). The same trend occurred in the striatum. 
UCMS decreased CD31+Desmin+ cells by 27% (p<0.01) as compared to LZR- and OZR-Controls, 
while in exercise, these cells were higher by 32% (p<0.01) compared to controls. Exercise also 
improved MVD by 25% (p<0.01) in LZR-UCMS+Ex, and also improved OZR-UCMS+Ex. MVD. 
The CD31+ cells mirrored the CD31+Desmin+ results in both the cortex and striatum for all 
treatment groups.         
Figure 3-2 illustrates mRNA expression and protein levels of angiogenic markers, VEGF 
and TSP-1. There were no significant changes in mRNA expression of VEGF between treatment 
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groups (Fig. 3-2A), along with no change in protein levels (Fig. 3-2B). In TSP-1, no significant 
changes in mRNA expression were found between treatment groups (Fig. 3-2C), but OZR-UCMS 
had a significant decrease in TSP-1 protein levels as compared to OZR-Control and OZR-Ex 
(p<0.01; Fig. 3-2D). Figure 3-3 represents mRNA expression in several oxidative stress markers. 
There were also no significant changes in mRNA expression between groups with catalase, SOD, 
GSR, or Nox2 (Fig. 3-3A-D). No significant changes in mRNA expression occurred in CD68, a 
macrophage marker (Fig. 3-3).     
         
Discussion 
The results outlined here are part of preliminary data on the change in cerebral MVD during 
the comorbidity of MetS and depression, and what effect exercise had on the microvascular 
rarefaction associated with these conditions. Our data suggests that globally in LZRs, UCMS 
decreased cerebro-angiogenesis but this can be attenuated with the addition of exercise. In OZRs, 
UCMS did not further decrease angiogenesis but exercise did improve MetS-derived 
microvascular rarefaction.  Also, when exercise was in combination with UCMS in OZRs, MVD 
was augmented as compared to OZR-Controls. Interestingly, there were no significant changes 
seen in mRNA expression of angiogenesis or oxidative markers. The lack of variation in mRNA 
expression between treatment groups could suggest that angiogenesis had already occurred in the 
brain, and transcription of these markers was back to basal levels.   
The effect of depression on MVD has not been thoroughly studied. The present study 
showed that CD31+Desmin+ cells were decreased with UCMS. There are several possible 
mechanisms that could have induced microvascular rarefaction. Patients with recurrent depressive 
disorder had lower circulating VEGF levels, which would attenuate angiogenesis (40). Endothelial 
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progenitor cell numbers have also been found to be decreased in depressed patients, slowing 
angiogenesis in the brain (41). The elevated stress response associated with depression causes an 
increase in cortisol levels (16). Previous studies have also shown glucocorticoids can attenuate 
angiogenesis by inhibiting proliferation of cerebrovascular endothelial cells (21). In addition, 
pericyte apoptosis occurs with increased cortisol levels, where the glucocorticoid binds to 
receptors expressed on the pericytes, but when pericytes were treated with a glucocorticoid 
receptor antagonist, glucocorticoid-induced apoptosis was inhibited (24).   
Exercise has been shown to reduce the physical symptoms of MetS and depression but also 
improve the pathophysiologies associated with each of the conditions (9,29,42–44). Therefore, it 
was hypothesized that microvessel density would be higher with exercise in pre-existing MetS and 
in the comorbidity between MetS and depression. We have shown that MVD was higher with 
exercise in both LZRs and OZRs. Further, we also observed an improved MVD in LZR- and OZR-
UCMS+Ex. NO is important in capillary recruitment. One possible factor that could have 
contributed to the increase in cerebral MVD could be the increase in NO production following 
exercise. Exercise increases NO bioavailability in several ways including: increased eNOS 
expression (45–47), increased SOD activity (48), and reduced ROS production from NOX2 
(49,50) in skeletal muscle vasculature. Thus, NO bioavailability would be higher in the exercise 
groups, possibly leading to higher MVD. In addition, during acute bouts of exercise, mechanical 
forces such as shear stress and passive stretch lead to enhanced expression of angiogenic factors, 
including VEGF (51). Muscle contraction increases VEGF in the muscle interstitium, where 
VEGF acts on its receptors within the capillary endothelium to stimulate angiogenic processes (9).  
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Limitations and Future Directions 
  One reason there were no significant changes in mRNA expression in any of the genes 
examined could be attributed to the variability in time it took to isolate and section the brain at 
time of terminal surgery. The period of time the brain was out of the rat to when it was flash frozen 
was not standardized, therefore, RNA degradation could have occurred. Stress has been known to 
cause different physical effects in individuals (52,53). Exercise could also have been a stressor to 
certain rats, especially in the OZRs. The individual response of the animals to stress and exercise 
may have contributed to the variability in mRNA expression, influencing the statistical power of 
the data and preventing small changes to be detected.  
Even though RT-PCR did not reveal any significant changes in mRNA expression, it was 
still important to determine if protein levels changed because mRNA to protein synthesis is not 
guaranteed (54,55). The process of making protein from the mRNA transcript could be disrupted 
by many different mechanisms including: post-transcriptional adaptations, regulation by 
microRNAs, change in secondary structure of the transcript, disruption in ribosomal subunit 
recruitment, and proteasome activity (56–58). A change in any of these mechanisms could cause 
a decrease in protein synthesis or even an increase; therefore, western blots would need to be 
performed to determine if protein levels were affected by the experimental conditions. 
Western blots for catalase, SOD, GSR, Nox2, and CD68 should have been done to 
determine the protein expression in the brain for each of these genes. Tissue is limited due to the 
many experiments already performed on the brain. ELISAs for VEGF and TSP-1 on brain 
homogenate are shown in this chapter, however, this is whole brain homogenate and more specific 
regional data is needed for correct evaluation of MVD changes in the cortex and striatum. It would 
be beneficial to separate these two regions and look at protein and mRNA expression in each. This 
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would allow for direct comparison between the IHC results and factors that may be contributing 
to the higher MVD in exercise and lower MVD in UCMS.   
RT-PCR and western blots for members of the MMP family should also be performed on 
the brain as these proteins are involved in angiogenesis. MMPs help with the degradation of the 
vascular basement membrane and remodeling of the ECM to allow endothelial cells to migrate 
and invade the surrounding tissue.  They also enhance angiogenesis by several methods including: 
helping to detach pericytes from vessels, releasing ECM-bound angiogenic growth factors, 
exposing cryptic pro-angiogenic integrin binding sites in the ECM, generating pro-migratory ECM 
component fragments, and cleaving endothelial cell-cell adhesion.  In contrast, MMPs can also 
inhibit angiogenesis by proteolytic cleavage of certain collagen chains, plasminogen, and certain 
receptor ligand-binding domains (59). A recent study found that pericyte-release of MMP-9 may 
contribute to early blood-brain barrier degradation after injury (60). Another target for PCR and 
westerns could be thromboxane A2. This metabolite, along with ATP, is released by platelets into 
the brain where they both act as potent constrictors of pericytes. Following constriction of the 
pericytes, contraction of the adjoining blood vessel wall would occur and could affect cerebral 
blood flow (61).    
Another experiment that could have been done involves IHC probing for CD31 and Ki67. 
Unfortunately, we do not have enough brain slices to complete the investigation, nor are the slices 
reliably fresh to provide proper results. Ki67 is used as a cell proliferation marker because during 
mitosis, the Ki67 antigen is expressed on the surface of chromosomes. The colocalization of CD31 
and Ki67 would indicate endothelial cells that are proliferating, giving a better idea to the extent 
of angiogenesis occurring within the brain. This process would involve the same procedure as the 
CD31 and desmin IHC previously shown.   
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 An increase in peroxynitrite levels can cause a reduction in NO bioavailability, but also 
pericyte contraction (62). In healthy conditions, pericytes help to regulate blood flow by 
contracting or relaxing (63). If peroxynitrite levels are chronically high, such as in MetS, pericyte 
contraction could become chronic and affect blood flow in the brain. Thus, staining for 
nitrotyrosine in the brain could have been beneficial to assess the amount of peroxynitrite present. 
Staining for nitrotyrosine would serve two purposes: 1) to support that the microvascular 
dysfunction shown in UCMS was at least in part mediated by ROS production and; 2) estimate the 
amount of pericyte dysfunction that would lead to chronic constriction of cerebral blood vessels.  
Collagen staining could have provided evidence for tissue remodeling due to the fibrotic 
response induced by pericyte death (61). Perivascular fibroblasts are recruited to sites of necrotic 
capillary pericytes and deposit extracellular matrix molecules that form a fibrotic scar within the 
brain. This could cause a number of problems including a disruption in neuronal signaling and 
cerebral perfusion (61). To evaluate the number of pericytes that are damaged in the case of 
decreased MVD, TUNEL and desmin staining could have been used to show DNA-fragmentation 
within pericytes. Paired with collagen staining, we would have been able to determine the sites of 
tissue remodeling and compare that to pericyte damage/apoptosis.   
 Monocyte-derived macrophages secrete VEGF-A, which seems to be crucial to induction 
of angiogenesis in tissue repair. Both M1 and M2 macrophage phenotypes are suggested to be 
involved with angiogenesis, in which M1 macrophages express genes involved with angiogenesis 
initiation and M2 macrophages secrete MMP-9 and recruit pericytes (64). Macrophages interact 
directly with pericytes, promoting pericyte-endothelial interactions. Macrophages also stimulate 
collateral artery diameter enlargement through smooth muscle cell hypertrophy and proliferation 
(65). Therefore, macrophage recruitment could have been evaluated in order to explain the higher 
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MVD with exercise. Staining brain slices with CXCL9 or CD86 would detect M1 macrophages 
and CXCR2 or CD23 would mark M2 macrophages (66). Flow cytometry could have been done 
on fresh brain slices to separate the macrophage phenotypes and compare population sizes.    
 
Clinical Implications and Conclusions 
 Many pathologies that result in poor cardiovascular outcomes stem from vascular 
dysfunction, whether that dysfunction is in the endothelium or is due to a reduction in perfusion. 
The data presented here show that UCMS has an effect on cerebral angiogenesis and causes a loss 
of MVD in healthy animals. More importantly, exercise augments MVD in pre-existing MetS and 
in the case of the comorbidity between UCMS and MetS. Clinically, these data are relevant 
because they suggest a possible mechanism contributing to loss of MVD. These results also 
suggest that exercise can be used as a therapeutic for patients.   
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Figure 3-1. Quantification of CD31/Desmin+ cells in the cortex and striatum. A, B) CD31+ and 
CD31+Desmin+cells in the cortex were decreased with UCMS in LZRs but not in OZRs. Increased in both 
Ex and UCMS+Ex; C, D) CD31+ and CD31+Desmin+cells in the cortex were decreased with UCMS in 
LZRs but not in OZRs. Increased in both Ex and UCMS+E. n = 6-8/group. Mean ± SEM. *p<0.01 vs. 
control, +p<0.05 vs. UCMS, ^p<0.05 vs. Ex. Please see text for additional details.  
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Figure 3-2. mRNA and protein expression of angiogenic factors in the brain. A) There were no significant 
changes in VEGF mRNA expression between treatment groups; B) There were no changes seen in VEGF 
protein expression between groups; C) There were no significant changes in TSP-1 mRNA expression 
between treatment groups; D) There was a significant decrease in TSP-1 protein levels in OZR-UCMS as 
compared to OZR-Control and -Ex. n = 6-8/group. Mean ± SEM. *p<0.01.  
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Figure 3-3. mRNA expression of oxidative stress markers in 
the brain. A) There were no significant changes in catalase 
mRNA expression between treatment groups; B) There were 
no significant changes in SOD mRNA expression between 
treatment groups; C) There were no significant changes in 
glutathione reductase (GSR) mRNA expression between 
treatment groups; D) There were no significant changes in 
Nox2 mRNA expression between treatment groups; E) There 
were no significant changes in CD68 mRNA expression 
between treatment groups. n = 6-8/group. Mean ± SEM.  
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CHAPTER 4 : Dissertation Discussion  
 
The effect of the comorbidity between MetS and depression on the peripheral 
microvasculature was unknown. Previous studies had examined the causative mechanisms of MetS 
and depression separately, but this dissertation focused on determining the impact of the 
comorbidity on the microvasculature of the skeletal muscle and brain, along with MVD. The 
studies performed previously have suggested a direct association between the vasculopathy caused 
by each disorder and the increase in oxidative stress on vascular reactivity and MVD. Poor 
cardiovascular outcomes are brought on by the endothelial dysfunction caused by MetS and 
depression.  Therefore, it was important to determine if depression exacerbated the vascular 
dysfunction already present with MetS. This study used exercise as a therapeutic, which has been 
proven previously to augment NO bioavailability and decrease ROS, to improve endothelium-
dependent dilation response in OZRs subjected to UCMS. Further, exercise attenuated loss of 
MVD.  
 The work detailed in this dissertation used the obese Zucker rat, a model of MetS, to 
determine that: 1) UCMS causes peripheral microvascular dysfunction in LZRs similar to that seen 
in OZRs; 2) Peripheral microvascular dysfunction seen in OZRs was not exacerbated with UCMS; 
3) the peripheral microvascular dysfunction and loss of MVD are caused by reduced NO 
bioavailability and increase in oxidative stress; and 4) exercise improves peripheral microvascular 
dysfunction and rarefaction by increasing NO.        
 The second chapter of this dissertation focused on characterizing the effect of MetS and 
depression, together, on the skeletal muscle arterioles using an in vitro pressurized myobath system 
to evaluate endothelium-dependent dilation and constriction response. Previous studies from our 
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collaborators have established the independent effects of MetS on the skeletal muscle arterioles 
and the effects of depression on the aorta (1,2). In both cases, endothelium-dependent dilation was 
impaired but did not find a significant change in constriction response. The study presented in 
Chapter 2 subjected OZRs and LZRs to UCMS for 8 weeks, and at the end of the 8 weeks of 
treatment GAs were isolated to determine dose response to Ach and PE. A significant reduction in 
endothelium-dependent dilation in LZR-UCMS but the same impairment was not seen in OZR-
UCMS. Both LZR- and OZR-UCMS endothelium-independent dilation were attenuated, and 
constriction response was augmented only in OZR-UCMS. Treatment with the ROS scavenger, 
TEMPOL, increased dilation response in LZR-UCMS, OZR-Control, and OZR-UCMS.  As to be 
expected, treatment with a NOS inhibitor, LNAME severely blunted LZR- and OZR-Control 
endothelium-dependent dilation. NO levels were lower in LZR-UCMS compared to their controls 
but did not significantly change between OZR-Control and OZR-UCMS. The same trends were 
seen with ROS levels in the respective groups.   
 The findings of this chapter provide evidence that a severe decrease in NO levels induced 
by UCMS and the added increase in ROS levels was the main cause of endothelium-dependent 
and -independent dilation in LZRs. The results of TEMPOL and LNAME treatment support this 
theory. In OZRs, the effect of UCMS on endothelium-dependent dilation is less drastic, which 
could be due to the fact that OZRs already have elevated ROS levels and reduced NO levels. This 
suggests the pre-existing impairment in OZRs may make them less susceptible to UCMS effects. 
The interesting finding involves the attenuation of OZR endothelium-independent dilation, which 
seems to be due to another NO-independent mechanism. Elevated thromboxane or Ang II could 
be the cause of the impairment, but further experiments are needed to confirm this hypothesis. 
Both of these metabolites have been shown to directly affect endothelium dilator function (3–6).  
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 The third chapter aimed to explore the possibility of using exercise as a therapeutic during 
the comorbidity of MetS and UCMS. This chapter built off the second chapter directly, meaning 
the same animals previously used in LZR- and OZR-Control and UCMS were used again, only 
LZR- and OZR-Ex and UCMS+Ex groups were added. Exercise by itself improved endothelium-
dependent dilation in both LZRs and OZRs. It did not influence endothelium-independent dilation 
in LZRs; however, OZR-UCMS EID was significantly improved. Acute TEMPOL treatment did 
not further augment endothelium-dependent dilation in LZR- and OZR-Ex, but LNAME once 
again abolished dilation response in these groups. With exercise, NO production was significantly 
increased in both LZRs and OZRs as compared to controls. Of note, LZR-Ex had higher levels of 
ROS as compared to LZR-Control but ROS levels did not change in OZR-Ex. The most novel 
finding of this chapter was that exercise eliminated the deleterious effects of UCMS in LZR- and 
OZR-UCMS+Ex. In fact, OZR-UCMS+Ex EDD was improved beyond control values. 
Endothelium-independent dilation in both LZR- and OZR-UCMS+Ex was augmented as 
compared to UCMS groups. No further improvement was seen with TEMPOL and these effects 
were abolished with LNAME treatment. NO levels were subsequently increased in LZR- and 
OZR-UCM+Ex, while ROS levels remained high in these groups. 
The outcomes of this chapter suggest that exposure to UCMS in LZRs resulted in vascular 
pathologies similar to those presented in OZR-Controls but without the other major changes in 
body mass, glucose, or lipid profile. Interestingly, the initial hypothesis for this paper was incorrect 
because exposure to UCMS in OZR did not further affect EDD when we had speculated that it 
would. The principle finding was that when Ex training was combined with UCMS, GA function 
was significantly improved in both LZRs and OZRs.  
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LZR-UCMS sustained EID dysfunction, which means the vascular smooth muscle was 
affected. There are several mechanisms that could damage the smooth muscle and most involve 
cell signaling dysfunction on the level of second messengers and their receptors. Previous studies 
have shown that an increase in cortisol levels, as seen in MetS and UCMS, can inhibit cyclic 
adenosine monophosphate expression; therefore, myosin light chain kinase activity is not blocked 
leading to vasoconstriction (7). Sustained high cortisol levels also result in overproduction of Ang 
II, a vasoconstrictor. Ang II directly effects the blood vessel but also causes an increase in ET-1, 
TxA2, and ROS through the activation of AT1 receptors. Thus, increased circulating Ang II causes 
vasoconstriction and smooth muscle damage (8). Another secondary messenger, soluble guanylyl 
cyclase, is inhibited by increased levels of ROS. This disrupts the action of NO on the smooth 
muscle and reduces vasodilatory response (9,10). Furthermore, increased cyclooxygenase 
signaling can lead to an imbalance of PGI2 and TxA2, causing an increase in TxA2. An increase in 
TxA2 induces vasoconstriction and smooth muscle cell dysfunction (5,11). 
There is a possibility that the elevated cortisol seen in the Ex and UCMS+Ex groups were 
caused by the forced treadmill Ex protocol. The rats were made to run to keep total work similar 
between the species. It is not surprising that this could cause some stress in the animals. The 
increase in cortisol could have caused an increase in hydrogen peroxide, superoxide, and 
peroxynitrite (12), which perhaps explains why higher ROS levels were seen in LZR-Ex and -
UCMS+Ex. It is known that DHE can interact with hydrogen peroxide and peroxynitrite as well 
as superoxide, meaning fluorescence intensity can only give a global measure of oxidative stress. 
Thus, the fact that ROS levels were higher in LZR-Ex and -UCMS+Ex could mean that hydrogen 
peroxide was significantly increased and not just superoxide. Exercise can increase hydrogen 
peroxide, where it acts as a vasodilator (13,14). This is a limitation of this chapter because some 
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of the improvement to EDD could be from hydrogen peroxide production in the UCMS+Ex 
groups.  
The fourth chapter of this dissertation aimed to determine whether MVD in the brain was 
influenced by the comorbidity between MetS and depression. Ex training was also employed to 
see if MVD loss due to MetS and depression could be prevented. The first experiment performed 
was double IHC for the endothelial cell marker, CD31, and a pericyte marker, desmin. Pericytes 
are important for both microvessel function and angiogenesis. The CD31/Desmin+ cells within the 
cortex and striatum were considered to be pro-angiogenic. UCMS significantly decreased MVD 
in LZR-UCMS but was not changed in OZR-UCMS. In LZR- and OZR-Ex, MVD was increased 
and when coupled with UCMS, exercise improved MVD in both LZR- and OZR-UCMS+Ex. RT-
PCR showed no differences in mRNA expression between groups in any of the angiogenic and 
oxidative stress markers examined.  
All of the chapters presented here are connected, meaning the future directions of this 
research are interrelated. MetS and depression effect many different systems/mechanisms of the 
body and within those mechanisms are feed-forward and feed-back loops. Exercise also influences 
some of the same systems and more. In this regard, there are many avenues in which the research 
can branch, but for the sake of brevity this dissertation will only detail a few target areas.  
MetS, depression, and exercise are the main focuses of this dissertation. There are several 
aspects of the studies presented previously that could be changed. For instance, the behavioral and 
physical characteristics of the rats undergoing UCMS and Ex could be further pursued. This could 
include better coat score analysis, implementation of the sucrose splash test, and perhaps use of 
the elevated plus maze to examine changes in behavior. Assessment of fat deposition could have 
been tracked using a rodent DEXA. Metabolic cages would have provided a more accurate way of 
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measuring food intake, and a way to separate urine and feces samples so that circulating levels of 
metabolites of interest could be measured.  
 The first logical future experiment would be to determine the impact of UCMS on the 
arachidonic acid pathway in pre-existing MetS. Previous studies have shown that circulating PGI2 
levels are decreased and TxA2 are increased in OZRs as compared to LZRs (4). This study also 
showed that endothelium-dependent dilation was impaired in skeletal muscle arterioles. Therefore, 
the impairment in EDD in LZRs and OZRs along with the attenuation of EID in LZRs, may be 
partially due to an imbalance of PGI2 and TxA2. Future experiments would involve microvessels, 
MCAs or GAs, hung in a pressurized myobath system and vessel reactivity would be assessed. 
The vessels would be exposed to increasing doses of iloprost, a synthetic analogue of PGI2, to 
evaluate dilation response in control, UCMS, Ex, and UCMS+Ex LZRs and OZRs. 
Vasoconstriction would be assessed by increasing doses of U46618, a TxA2 mimetic. Incubation 
with indomethacin, a COX antagonist, would help to determine how much of the dilation response 
is due to arachidonic acid pathway involvement versus the NO pathway. Whether the mechanism 
is caused by dysfunction in COX2 or in synthase activity needs to be clarified, and incubation with 
carboxyheptyl imidazole (CHI), a TxA2 synthase inhibitor, in addition to the indomethacin 
incubation would help verify this. ELISAs or westerns should be done to examine the protein 
expression of TxA2 and PGI2 derivatives, and then compared to RT-PCR results for their respective 
synthases.  These experiments would give a comprehensive view into how the arachidonic acid 
pathway is affected by the comorbidity between MetS and UCMS, especially when paired with 
the results previously outlined in this dissertation.  
Exercise has been shown to increase production of hydrogen peroxide, where this molecule 
causes vasodilation. Our results showed an increase in ROS levels in LZR-Ex and -UCMS+Ex, 
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when we would have expected a decrease as compared to LZR-UCMS. TEMPOL incubation did 
not further improve endothelium-dependent dilation in LZR-Control, -Ex, or -UCMS+Ex. It also 
did not increase endothelium-dependent dilation in OZR-Ex and -UCMS+Ex. Hydrogen peroxide 
could have partially caused the augmentation of EDD seen in the Ex and UCMS+Ex groups, and 
also explain the increase in ROS in LZR-Ex and -UCMS+Ex due to the previously outlined 
limitations in DHE staining. Therefore, to determine how much of the improvement was due to 
NO versus hydrogen peroxide, AmplexRed could be used to detect hydrogen peroxide levels as 
EPR does not detect nonradical oxidants (15). TEMPOL catalyzes the process of turning 
superoxide into oxygen and hydrogen peroxide (16). It would, therefore, be interesting to test if 
adding TEMPOL to the Ex and UCMS+Ex vessels when probing for DHE would increase 
fluorescence intensity even further. To determine if hydrogen peroxide was causing the increase 
in fluorescence intensity, the vessels exposed to DHE could also have been incubated with 
catalase, a hydrogen peroxide scavenger. Further, endothelium-dependent dilation could be 
assessed in the presence of catalase and compared to the maximum dilation found with TEMPOL, 
to differentiate how much of the augmentation was because of increased NO bioavailability or 
hydrogen peroxide production. Mitochondrial production of hydrogen peroxide is increased in 
nonphosphorylating respiration during endurance exercise (17,18). It may be, therefore, beneficial 
to measure mitochondrial function through amperometric O2 sensors or ATP production via 
bioluminescence (19,20).   
VEGF expression has been thoroughly studied as a regulator of angiogenesis (21). Tang et 
al. (22) found that after one hour of exercise, VEGF transcriptional activity increased 38% in the 
brain, mRNA levels increased by 88%, and protein levels increased by 66%. Further, Tang and 
colleagues showed the major increase in VEGF expression occurred in the hippocampal region of 
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the brain. The hippocampus has inhibitory control over HPA-axis activity and has a role in stress 
regulation (23). Depression has been shown to alter the hippocampus, including causing a decrease 
in VEGF expression in the region, which could contribute to the downregulation of neurogenesis 
by stress (24). A study by Morland et al. (25), illustrated the effect of exercise-induced lactate 
release on brain angiogenesis. They found that pericyte-like cells express lactate receptor, HCAR1, 
and when this receptor is activated, VEGFA expression and cerebral angiogenesis is induced. This 
discovery could be interesting to expand on in the realm of using exercise to improve MetS and 
depression. We have shown in this dissertation that MVD is decreased with MetS and depression, 
but that exercise can improve MVD in these groups. Lactate could be involved in this process as 
evidenced by the study by Morland et al. A future study expanding on the experiments presented 
in this dissertation could employ lactate injections in place of exercise and include the following 
groups in LZRs and OZRs: control, UCMS, daily lactate injections, and UCMS+lactate injections.   
After 8 weeks of UCMS and lactate injections, evaluations of microvessel reactivity and 
MVD could be performed. Briefly, this would include baseline endothelium-dependent dilation 
response in the microvessels along with endothelium-dependent dilation response after incubations 
with TEMPOL and L-NAME, and IHC with CD31 and desmin to determine MVD in the brain.  
This experiment would isolate one aspect of Ex, lactate production, and demonstrate the ability of 
lactate to enhance cerebral angiogenesis. In addition, probing for CD31 and Ki67 would indicate 
endothelial cells that are proliferating and give a better idea to the extent of angiogenesis occurring 
within the brain. To evaluate involvement of pericytes expressing HCAR1 in cerebral 
angiogenesis, co-staining with desmin and HCAR1 antibodies could be used to quantify the 
number of pericytes in each treatment group that is expressing the receptor. Thus, if the number of 
HCAR1-expressing pericytes is higher in the lactate injection groups, it may suggest that lactate 
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is mediating the increase in MVD. Determining VEGFA expression would also be important and 
would be done via western blots and RT-PCR. VEGFA expression would be expected to rise in 
the lactate injection groups, in addition to the increase in HCAR1-expressing pericytes. Such a 
study could offer an alternative therapy to Ex for patients that may be unwilling or unable to daily.     
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